≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Epileptic seizures related to alcohol

DOID EFO Endpoint Browser PheWeb

EPISEIZALCO

epilepsy: A brain disorder characterized by episodes of abnormally increased neuronal discharge resulting in transient episodes of sensory or motor neurological dysfunction, or psychic dysfunction. These episodes may or may not be associated with loss of consciousness or convulsions.

Suggest a new description

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — G40.51
  • Cause of death: ICD-10 — G40.51

2 out of 7 registries used, show all original rules.

221

4. Check minimum number of events

None

221

5. Include endpoints

None

221

6. Filter based on genotype QC (FinnGen only)

214

Control definitions (FinnGen only)

Controls for this endpoint are individuals that are not cases.

Extra metadata

Level in the ICD hierarchy
2
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
G405
Name in latin
Ictus epileptici ex usu alcohol

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 3694 714 2952
Only index persons 2804 567 2237
Unadjusted period prevalence (%)
Whole population 0.07 0.02 0.08
Only index persons 0.07 0.02 0.09
Median age at first event (years)
Whole population 51.19 51.05 51.18
Only index persons 51.40 51.11 51.48

-FinnGen-

Key figures

All Female Male
Number of individuals 214 44 170
Unadjusted period prevalence (%) 0.07 0.02 0.08
Median age at first event (years) 51.86 47.35 53.03

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
221
Matched controls
2210
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G40.51
ICD-10 Finland
Epileptic seizures related to alcohol
+∞
320.1
221
*
R56.8
ICD-10 Finland
Other and unspecified convulsions
80.2
243.3
158
67
F10.1
ICD-10 Finland
Mental and behavioural disorders due to use of alcohol, Harmful use
44.5
189.6
160
123
F10.31
ICD-10 Finland
Withdrawal symptoms caused by alcohol with seizures
100.6
140.1
74
11
F10.29
ICD-10 Finland
Addiction caused by alcohol UNS
28.3
109.2
83
46
G40.9
ICD-10 Finland
Epilepsy, unspecified
31.6
102.6
73
34
111
Kela drug reimbursment
Epilepsy and comparable convulsive disorders
22.2
93.6
79
54
P15
ICPC
Chronic alcohol abuse
23.7
90.7
73
45
F10.20
ICD-10 Finland
Alcohol dependence currently independent
27.8
75.9
55
26
F10.25
ICD-10 Finland
Alcohol dependence continuous use
27.8
75.9
55
26
F10.40
ICD-10 Finland
Withdrawal symptoms and delirium caused by alcohol without seizures
42.4
75.5
47
14
G40.22
ICD-10 Finland
Complex partial epileptic seizure with secondary generalization
34.1
66.3
44
16
F10.00
ICD-10 Finland
Alcohol-related acute intoxication uncomplicated
28.8
65.2
46
20
N03AX14
ATC
levetiracetam; systemic
23.6
65.0
50
27
F10.39
ICD-10 Finland
Withdrawal symptoms caused by alcohol UNS
33.1
64.3
43
16
F10.09
ICD-10 Finland
Alcohol intoxication UNS
20.2
63.6
53
34
F10.24
ICD-10 Finland
Alcohol depence active use
22.7
60.3
47
26
N07BB01
ATC
disulfiram; oral
12.4
57.7
67
75
F10.26
ICD-10 Finland
Alcohol dependence periodic alcoholism
23.0
52.2
40
21
182
Kela drug reimbursment
Brivaracetam, eslikarbazepin, gabapentin, lacosamide, levetiracetam, perampanel, pregabalin, tiagabin and zonisamide
23.0
52.2
40
21
N03AG01
ATC
valproic acid; systemic, rectal
11.9
51.5
60
67
N03AF01
ATC
carbamazepine; oral, rectal
13.1
49.5
53
52
AA1AD
NOMESCO Finland
CT of head and brain
6.3
41.8
133
427
T36
ICD-10 Finland
Poisoning by systemic antibiotics
10.8
39.0
47
54
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
5.8
38.0
124
400
S06.5
ICD-10 Finland
Traumatic subdural haemorrhage
16.7
37.3
33
23
N03AF02
ATC
oxcarbazepine; oral
12.9
36.6
38
35
S01.0
ICD-10 Finland
Open wound of scalp
7.5
36.3
63
112
N05BA02
ATC
chlordiazepoxide; systemic
13.2
34.4
35
31
X69
ICD-10 Finland
Intentional self-poisoning by and exposure to other and unspecified chemicals and noxious substances
12.5
34.0
36
34
W19
ICD-10 Finland
Unspecified fall
7.0
31.8
57
104
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
5.5
31.8
86
231
E87.1
ICD-10 Finland
Hypo-osmolality and hyponatraemia
11.1
31.5
36
38
P16
ICPC
Acute alcohol abuse
13.2
29.8
30
26
N05BA01
ATC
diazepam; systemic, rectal
5.5
28.5
71
176
F10.9
ICD-10 Finland
Mental and behavioural disorders due to use of alcohol, Unspecified mental and behavioural disorder
39.8
27.4
34
10
F10.2
ICD-10 Finland
Mental and behavioural disorders due to use of alcohol, Dependence syndrome
23.6
25.3
36
18
F10.49
ICD-10 Finland
Withdrawal symptoms and delirium caused by alcohol without information about seizures
43.1
24.6
30
8
F10.41
ICD-10 Finland
Withdrawal symptoms and delirium caused by alcohol with seizures
76.4
24.4
27
*
G41.9
ICD-10 Finland
Status epilepticus, unspecified
73.2
23.4
26
*
F10.21
ICD-10 Finland
Alcohol dependence currently abstinent, but staying in restrictive environment
22.3
21.5
31
16
F32.9
ICD-10 Finland
Depressive episode, unspecified
5.0
21.2
54
134
F10.06
ICD-10 Finland
Alcohol-related acute intoxication with seizures
85.3
21.1
23
*
G31.2
ICD-10 Finland
Degeneration of nervous system due to alcohol
25.5
21.0
29
13
N06AB04
ATC
citalopram; systemic
4.1
19.9
71
228
S06.0
ICD-10 Finland
Concussion
4.7
19.2
52
135
G40
ICD-10 Finland
Epilepsy
33.4
18.8
24
8
N05AA02
ATC
levomepromazine; systemic
6.6
18.5
32
55
N06AX11
ATC
mirtazapine; oral
3.4
18.3
112
508
F10.30
ICD-10 Finland
Withdrawal symptoms caused by alcohol uncomplicated
17.9
17.5
27
17
X59
ICD-10 Finland
Exposure to unspecified factor
3.7
17.3
75
272
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
3.6
16.9
74
270
N05CF01
ATC
zopiclone; oral
3.3
16.5
100
445
K70.1
ICD-10 Finland
Alcoholic hepatitis
65.0
16.0
18
*
N05AH04
ATC
quetiapine; oral
3.5
15.4
68
248
A98
ICPC
Health maint/preventive medicine
0.3
15.4
164
2025
S42.2
ICD-10 Finland
Fracture of upper end of humerus
7.4
15.2
23
34
G40.29
ICD-10 Finland
Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures
14.7
15.1
25
19
K70.3
ICD-10 Finland
Alcoholic cirrhosis of liver
20.2
15.0
22
12
N05CD07
ATC
temazepam; oral
4.1
14.7
46
132
E87.6
ICD-10 Finland
Hypokalaemia
6.6
14.2
24
40
3039X
ICD-9 Finland
Alcohol dependence syndrome, Other and unspecified alcohol dependence
14.9
14.1
23
17
N03AB02
ATC
phenytoin; systemic
16.4
13.4
21
14
F10.03
ICD-10 Finland
Alcohol-related acute intoxication with delirium
30.5
13.2
17
6
Z72.1
ICD-10 Finland
Alcohol use
13.5
12.4
21
17
WX892
NOMESCO Finland
Monitored bed care
4.4
12.4
34
88
N03AX18
ATC
lacosamide; systemic
22.9
12.2
17
8
N05AB01
ATC
dixyrazine; systemic
14.5
12.2
20
15
Y04.9
ICD-10 Finland
Assault by bodily force by unknown person
20.3
11.8
17
9
V03AA01, ,
ATC
9.7
11.6
23
26
NA1AD
NOMESCO Finland
Cervical spine CT examination
4.7
11.1
27
63
N88
ICPC
Epilepsy
45.8
11.0
13
*
W10
ICD-10 Finland
Fall on and from stairs and steps
5.0
11.0
25
55
S06.3
ICD-10 Finland
Focal brain injury
16.6
11.0
17
11
C07AA05
ATC
propranolol; systemic
2.9
10.7
62
260
F10.0
ICD-10 Finland
Mental and behavioural disorders due to use of alcohol, Acute intoxication
12.9
10.6
18
15
K86.00
ICD-10 Finland
Acute pancreatitis caused by alcohol
11.4
10.5
19
18
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
3.0
10.3
55
220
N03AX09
ATC
lamotrigine; oral
5.3
10.0
21
43
R41.0
ICD-10 Finland
Disorientation, unspecified
8.0
10.0
22
30
C03CA01
ATC
furosemide; systemic
2.6
9.8
74
355
F05.9
ICD-10 Finland
Delirium, unspecified
12.2
9.7
17
15
G40.20
ICD-10 Finland
Complex partial seizures with only alteration of consciousness
18.6
9.5
14
8
S02.20
ICD-10 Finland
Fracture of nasal bones, closed
13.2
9.5
16
13
WX730
NOMESCO Finland
Conventional respirator
13.2
9.5
16
13
K92.0
ICD-10 Finland
Haematemesis
9.3
9.5
19
22
K86.08
ICD-10 Finland
Alcohol-induced chronic pancreatitis
31.6
9.5
12
*
G40.89
ICD-10 Finland
Other epilepsy
31.6
9.5
12
*
F10.4
ICD-10 Finland
Mental and behavioural disorders due to use of alcohol, Withdrawal state with delirium
104.3
9.5
10
*
N05BA04
ATC
oxazepam; oral
2.6
9.3
69
326
R55
ICD-10 Finland
Syncope and collapse
3.3
9.3
38
129
T90.5
ICD-10 Finland
Sequelae of intracranial injury
12.2
9.2
16
14
G72.8
ICD-10 Finland
Other specified myopathies
10.7
9.2
17
17
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.6
9.1
73
358
G40.19
ICD-10 Finland
Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures
19.6
9.0
13
7
G40.12
ICD-10 Finland
Simple partial seizures with secondary generalization
19.6
9.0
13
7
N07
ICPC
Convulsion/seizure
52.1
8.7
10
*
G40.6
ICD-10 Finland
Grand mal seizures, unspecified (with or without petit mal)
52.1
8.7
10
*
A06AD11
ATC
lactulose; oral
3.2
8.7
39
140
N06AA12
ATC
doxepin; systemic
4.4
8.5
22
54
G41.0
ICD-10 Finland
Grand mal status epilepticus
93.5
8.5
9
*
G40.50
ICD-10 Finland
Epilepsia partialis continua [Kozhevnikof]
93.5
8.5
9
*
WYA30
NOMESCO Finland
Treatment of a patient needing special arrangements
3.7
8.4
28
83
183
Kela drug reimbursment
Lamotrigin and topiramate
15.2
8.3
13
9
R40.2
ICD-10 Finland
Coma, unspecified
18.0
8.2
12
7
S62.3
ICD-10 Finland
Fracture of other metacarpal bone
7.7
8.1
18
25
S00.0
ICD-10 Finland
Superficial injury of scalp
8.3
8.0
17
22
S82.6
ICD-10 Finland
Fracture of lateral malleolus
4.3
7.8
21
53
JN3AD
NOMESCO Finland
Abdominal CT examination
2.8
7.8
43
174
WX882
NOMESCO Finland
High dependency care
7.6
7.6
17
24
K70.9
ICD-10 Finland
Alcoholic liver disease, unspecified
26.0
7.6
10
*
I69.3
ICD-10 Finland
Sequelae of cerebral infarction
3.5
7.5
27
84
F02.89*G40.9
ICD-10 Finland
Dementia in epilepsy
82.8
7.5
8
*
F10.05
ICD-10 Finland
Alcohol-related acute intoxication with coma
82.8
7.5
8
*
G40.10
ICD-10 Finland
Simple partial seizures
82.8
7.5
8
*
XA800
NOMESCO Finland
Neuropsychological investigation
4.4
7.4
19
46
TPH07
NOMESCO Finland
Cathetrisation of artery
2.8
7.4
41
166
N05AX08
ATC
risperidone; systemic
3.3
7.4
29
96
2918A
ICD-9 Finland
Alcoholic psychoses, Other specified alcoholic psychosis
+∞
7.3
7
*
SPAT1227
SPAT
Substance abuse rehabilitation
16.4
7.3
11
7
R11
ICD-10 Finland
Nausea and vomiting
3.4
7.3
27
86
K29.2
ICD-10 Finland
Alcoholic gastritis
31.1
7.2
9
*
S00.9
ICD-10 Finland
Superficial injury of head, part unspecified
12.6
7.2
12
10
J69.0
ICD-10 Finland
Pneumonitis due to food and vomit
10.5
7.1
13
13
D07BA04
ATC
hydrocortisone and antiseptics; topical
3.3
7.1
28
93
Z2446
NOMESCO Finland
Social worker
3.6
7.1
24
72
Z53.2
ICD-10 Finland
Procedure not carried out because of patient's decision for other and unspecified reasons
8.0
7.0
15
20
K70.0
ICD-10 Finland
Alcoholic fatty liver
14.4
7.0
11
8
J44.8
ICD-10 Finland
Other specified chronic obstructive pulmonary disease
3.0
7.0
34
128
T74.1
ICD-10 Finland
Physical abuse
9.8
6.9
13
14
SPAT1265
SPAT
Breathalyser
11.5
6.9
12
11
F32.10
ICD-10 Finland
Moderate depressive episode without somatic syndrome
3.4
6.8
26
84
S02.30
ICD-10 Finland
Fracture of orbital floor, closed
17.4
6.8
10
6
WX872
NOMESCO Finland
Intensive care
3.4
6.8
25
79
G40.59
ICD-10 Finland
Other special epileptic syndromes
41.4
6.8
8
*
P18
ICPC
Medication abuse
23.3
6.7
9
*
N05BA09
ATC
clobazam; oral
23.3
6.7
9
*
F10.3
ICD-10 Finland
Mental and behavioural disorders due to use of alcohol, Withdrawal state
23.3
6.7
9
*
N05AD03
ATC
melperone; systemic
12.8
6.7
11
9
SPAT1309
SPAT
Guidance related to psychoactive substances / risk behaviour
6.0
6.6
17
30
X58
ICD-10 Finland
Exposure to other specified factors
2.5
6.6
45
202
R53
ICD-10 Finland
Malaise and fatigue
2.3
6.5
62
324
N03AE01
ATC
clonazepam; systemic
3.7
6.5
21
61
G40.1
ICD-10 Finland
Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures
71.8
6.5
7
*
I61.9
ICD-10 Finland
Intracerebral haemorrhage, unspecified
9.7
6.4
12
13
F60.30
ICD-10 Finland
Emotionally unstable personality disorder, impulsive
9.7
6.4
12
13
SPD00
NOMESCO Finland
Mucosa borne complete denture
18.7
6.3
9
5
G62.1
ICD-10 Finland
Alcoholic polyneuropathy
18.7
6.3
9
5
S06.2
ICD-10 Finland
Diffuse brain injury
18.7
6.3
9
5
G40.4
ICD-10 Finland
Other generalized epilepsy and epileptic syndromes
+∞
6.3
6
*
Y91.2
ICD-10 Finland
Severe alcohol intoxication
+∞
6.3
6
*
OAB43, ,
SPAT
0.3
6.2
13
439
A28
ICPC
Limited function/disability NOS
2.6
6.1
39
169
N06AB03
ATC
fluoxetine; oral
2.7
6.1
34
138
J15.9
ICD-10 Finland
Bacterial pneumonia, unspecified
3.1
6.0
26
91
F17.29
ICD-10 Finland
Addiction caused by tobacco UNS
7.6
6.0
13
18
F29
ICD-10 Finland
Unspecified nonorganic psychosis
4.2
6.0
16
40

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Neurology
13 [38004458]
2.0e+00
3.0e+00
3.3e+00
1.0e+50
3.7e+00
3.0e+00
2.2e+00
cases:33.48%
controls:6.65%
cases:36.65%
controls:2.71%
cases:10.41%
controls:0.41%
cases:57.01%
controls:0.00%
cases:11.59%
controls:0.32%
cases:38.61%
controls:2.91%
cases:45.86%
controls:8.32%
74
147
147
2063
81
60
140
2150
23
9
198
2201
126
0
95
2210
24
7
183
2202
78
63
124
2105
83
169
98
1863
Mental and behavioural disorders due to use of alcohol, Harmful use
F10.1 [45595844]
3.7e+00
4.1e+00
—
1.0e+50
—
3.9e+00
4.1e+00
cases:28.51%
controls:1.00%
cases:16.29%
controls:0.32%
—
—
cases:8.14%
controls:0.00%
—
—
cases:13.37%
controls:0.32%
cases:39.23%
controls:1.08%
63
22
158
2188
36
7
185
2203
—
18
0
203
2210
—
27
7
175
2161
71
22
110
2010
Psychiatry
26 [38004469]
2.1e+00
2.4e+00
2.3e+00
—
2.6e+00
2.1e+00
2.0e+00
cases:25.79%
controls:4.12%
cases:14.48%
controls:1.54%
cases:5.43%
controls:0.59%
—
—
cases:10.63%
controls:0.91%
cases:15.35%
controls:2.12%
cases:25.41%
controls:4.53%
57
91
164
2119
32
34
189
2176
12
13
209
2197
—
22
20
185
2189
31
46
171
2122
46
92
135
1940
Complex partial epileptic seizure with secondary generalization
G40.22 [2000502141]
2.9e+00
2.9e+00
—
1.0e+50
—
3.7e+00
3.3e+00
cases:4.07%
controls:0.23%
cases:4.07%
controls:0.23%
—
—
cases:2.26%
controls:0.00%
—
—
cases:8.42%
controls:0.23%
cases:11.60%
controls:0.49%
9
5
212
2205
9
5
212
2205
—
5
0
216
2210
—
17
5
185
2163
21
10
160
2022
valproic acid; oral, parenteral, rectal
N03AG01 [21604422]
2.5e+00
2.2e+00
2.3e+00
—
—
2.6e+00
3.0e+00
cases:9.95%
controls:0.86%
cases:6.33%
controls:0.72%
cases:2.71%
controls:0.27%
—
—
—
—
cases:10.40%
controls:0.88%
cases:18.23%
controls:1.08%
22
19
199
2191
14
16
207
2194
6
6
215
2204
—
—
21
19
181
2149
33
22
148
2010
temazepam; oral
N05CD07 [21604642]
1.9e+00
2.1e+00
2.3e+00
—
2.3e+00
2.1e+00
1.9e+00
cases:13.57%
controls:2.40%
cases:9.50%
controls:1.22%
cases:2.71%
controls:0.27%
—
—
cases:3.38%
controls:0.36%
cases:8.91%
controls:1.15%
cases:14.92%
controls:2.46%
30
53
191
2157
21
27
200
2183
6
6
215
2204
—
7
8
200
2201
18
25
184
2143
27
50
154
1982
Emergency Room Visit
ER [9203]
1.7e+00
1.9e+00
2.9e+00
—
2.0e+00
1.8e+00
1.7e+00
cases:65.16%
controls:25.34%
cases:43.89%
controls:10.68%
cases:19.46%
controls:1.27%
—
—
cases:11.59%
controls:1.67%
cases:42.08%
controls:10.56%
cases:69.06%
controls:29.68%
144
560
77
1650
97
236
124
1974
43
28
178
2182
—
24
37
183
2172
85
229
117
1939
125
603
56
1429
Inpatient Hospital
21 [8717]
1.4e+00
1.8e+00
2.2e+00
—
2.7e+00
2.0e+00
1.8e+00
cases:60.63%
controls:26.97%
cases:39.82%
controls:10.23%
cases:9.95%
controls:1.22%
—
—
cases:17.87%
controls:1.49%
cases:40.59%
controls:8.58%
cases:67.96%
controls:25.59%
134
596
87
1614
88
226
133
1984
22
27
199
2183
—
37
33
170
2176
82
186
120
1982
123
520
58
1512
General Practice
1 [38004446]
1.9e+00
2.3e+00
—
1.0e+50
3.0e+00
2.1e+00
2.2e+00
cases:37.10%
controls:7.92%
cases:25.34%
controls:3.39%
—
—
cases:13.12%
controls:0.00%
cases:11.59%
controls:0.63%
cases:23.27%
controls:3.69%
cases:50.28%
controls:9.89%
82
175
139
2035
56
75
165
2135
—
29
0
192
2210
24
14
183
2195
47
80
155
2088
91
201
90
1831
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
1.2e+00
1.8e+00
2.3e+00
1.0e+50
2.5e+00
1.5e+00
1.4e+00
cases:9.05%
controls:2.90%
cases:8.60%
controls:1.54%
cases:3.17%
controls:0.32%
cases:5.43%
controls:0.00%
cases:4.35%
controls:0.36%
cases:6.93%
controls:1.57%
cases:17.68%
controls:4.87%
20
64
201
2146
19
34
202
2176
7
7
214
2203
12
0
209
2210
9
8
198
2201
14
34
188
2134
32
99
149
1933
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
1.2e+00
1.7e+00
2.3e+00
1.0e+50
2.5e+00
1.3e+00
1.4e+00
cases:9.95%
controls:3.26%
cases:9.05%
controls:1.76%
cases:3.62%
controls:0.36%
cases:6.33%
controls:0.00%
cases:4.35%
controls:0.36%
cases:6.93%
controls:1.94%
cases:19.89%
controls:6.00%
22
72
199
2138
20
39
201
2171
8
8
213
2202
14
0
207
2210
9
8
198
2201
14
42
188
2126
36
122
145
1910
Supine thorax X-ray examination
GD1QA [2001303648]
2.0e+00
2.7e+00
—
1.0e+50
—
2.9e+00
2.6e+00
cases:5.43%
controls:0.77%
cases:4.07%
controls:0.27%
—
—
cases:2.71%
controls:0.00%
—
—
cases:5.45%
controls:0.32%
cases:12.15%
controls:0.98%
12
17
209
2193
9
6
212
2204
—
6
0
215
2210
—
11
7
191
2161
22
20
159
2012
Transferrin.carbohydrate deficient.disialo/Transferrin.total in Serum or Plasma
21573-1 [3003031]
2.4e+00
2.8e+00
—
—
—
2.9e+00
2.1e+00
cases:6.79%
controls:0.68%
cases:4.98%
controls:0.32%
—
—
—
—
—
—
cases:4.95%
controls:0.28%
cases:12.15%
controls:1.72%
15
15
206
2195
11
7
210
2203
—
—
—
10
6
192
2162
22
35
159
1997
carbamazepine; oral, rectal
N03AF01 [21604417]
2.6e+00
2.2e+00
—
—
—
2.5e+00
2.8e+00
cases:11.31%
controls:0.90%
cases:6.33%
controls:0.77%
—
—
—
—
—
—
cases:9.41%
controls:0.83%
cases:12.15%
controls:0.84%
25
20
196
2190
14
17
207
2193
—
—
—
19
18
183
2150
22
17
159
2015
diazepam; oral, parenteral, rectal
N05BA01 [21604566]
1.9e+00
1.7e+00
—
—
2.0e+00
2.0e+00
2.3e+00
cases:14.93%
controls:2.49%
cases:7.69%
controls:1.45%
—
—
—
—
cases:2.90%
controls:0.41%
cases:8.91%
controls:1.29%
cases:16.57%
controls:1.92%
33
55
188
2155
17
32
204
2178
—
—
6
9
201
2200
18
28
184
2140
30
39
151
1993
Creatine kinase [Enzymatic activity/volume] in Serum or Plasma
2157-6 [3007220]
1.5e+00
3.1e+00
—
1.0e+50
—
2.6e+00
2.0e+00
cases:9.50%
controls:2.26%
cases:9.05%
controls:0.45%
—
—
cases:9.50%
controls:0.00%
—
—
cases:7.92%
controls:0.65%
cases:18.78%
controls:2.90%
21
50
200
2160
20
10
201
2200
—
21
0
200
2210
—
16
14
186
2154
34
59
147
1973
Fall on same level from slipping, tripping and stumbling
W01 [45756243]
1.9e+00
2.5e+00
—
—
—
2.8e+00
1.8e+00
cases:14.48%
controls:2.53%
cases:8.14%
controls:0.72%
—
—
—
—
—
—
cases:9.90%
controls:0.69%
cases:19.34%
controls:3.64%
32
56
189
2154
18
16
203
2194
—
—
—
20
15
182
2153
35
74
146
1958
Other and unspecified convulsions
R56.8 [45602033]
4.8e+00
—
1.0e+50
1.0e+50
1.0e+50
—
4.1e+00
cases:21.72%
controls:0.23%
—
—
cases:7.69%
controls:0.00%
cases:14.48%
controls:0.00%
cases:3.38%
controls:0.00%
—
—
cases:23.76%
controls:0.49%
48
5
173
2205
—
17
0
204
2210
32
0
189
2210
7
0
200
2209
—
43
10
138
2022
disulfiram; oral
N07BB01 [21604821]
2.8e+00
2.6e+00
—
—
—
—
3.3e+00
cases:11.76%
controls:0.81%
cases:3.62%
controls:0.27%
—
—
—
—
—
—
—
—
cases:12.15%
controls:0.49%
26
18
195
2192
8
6
213
2204
—
—
—
—
22
10
159
2022
Internal Medicine
11 [38004456]
1.3e+00
1.7e+00
2.4e+00
—
1.2e+00
1.5e+00
1.6e+00
cases:46.15%
controls:18.33%
cases:34.39%
controls:8.55%
cases:13.57%
controls:1.40%
—
—
cases:5.80%
controls:1.86%
cases:29.21%
controls:8.16%
cases:53.04%
controls:19.29%
102
405
119
1805
76
189
145
2021
30
31
191
2179
—
12
41
195
2168
59
177
143
1991
96
392
85
1640
Emergency Medicine
93 [38004510]
7.2e-01
1.5e+00
2.7e+00
1.0e+50
1.9e+00
1.5e+00
9.0e-01
cases:9.50%
controls:4.84%
cases:11.31%
controls:2.85%
cases:4.52%
controls:0.32%
cases:11.76%
controls:0.00%
cases:3.38%
controls:0.50%
cases:11.88%
controls:2.86%
cases:20.99%
controls:9.74%
21
107
200
2103
25
63
196
2147
10
7
211
2203
26
0
195
2210
7
11
200
2198
24
62
178
2106
38
198
143
1834
pH of Serum or Plasma
2753-2 [3018418]
1.2e+00
1.7e+00
—
1.0e+50
2.7e+00
1.5e+00
1.4e+00
cases:6.79%
controls:2.22%
cases:6.33%
controls:1.27%
—
—
cases:3.62%
controls:0.00%
cases:3.86%
controls:0.27%
cases:4.95%
controls:1.15%
cases:12.15%
controls:3.30%
15
49
206
2161
14
28
207
2182
—
8
0
213
2210
8
6
199
2203
10
25
192
2143
22
67
159
1965
Outpatient Hospital
22 [8756]
8.4e-01
9.1e-01
2.2e+00
1.0e+50
1.7e+00
1.4e+00
1.3e+00
cases:36.20%
controls:19.64%
cases:16.74%
controls:7.47%
cases:6.33%
controls:0.72%
cases:11.31%
controls:0.00%
cases:3.86%
controls:0.72%
cases:18.32%
controls:5.26%
cases:48.07%
controls:20.23%
80
434
141
1776
37
165
184
2045
14
16
207
2194
25
0
196
2210
8
16
199
2193
37
114
165
2054
87
411
94
1621
quetiapine; oral
N05AH04 [21604544]
1.4e+00
1.4e+00
1.6e+00
—
2.1e+00
1.6e+00
1.8e+00
cases:7.24%
controls:1.86%
cases:4.98%
controls:1.31%
cases:2.26%
controls:0.45%
—
—
cases:2.90%
controls:0.36%
cases:6.93%
controls:1.43%
cases:13.26%
controls:2.56%
16
41
205
2169
11
29
210
2181
5
10
216
2200
—
6
8
201
2201
14
31
188
2137
24
52
157
1980
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
7.3e-01
1.1e+00
2.0e+00
—
2.7e+00
1.1e+00
1.3e+00
cases:9.05%
controls:4.57%
cases:6.79%
controls:2.44%
cases:3.62%
controls:0.50%
—
—
cases:3.86%
controls:0.27%
cases:7.43%
controls:2.54%
cases:21.55%
controls:7.14%
20
101
201
2109
15
54
206
2156
8
11
213
2199
—
8
6
199
2203
15
55
187
2113
39
145
142
1887
Outpatient Visit
OP [9202]
5.9e-01
6.0e-01
6.7e-01
4.5e+00
8.5e-01
5.9e-01
7.4e-01
cases:68.33%
controls:54.34%
cases:48.87%
controls:34.34%
cases:14.03%
controls:7.74%
cases:17.19%
controls:0.23%
cases:16.91%
controls:7.97%
cases:51.49%
controls:37.13%
cases:79.56%
controls:65.01%
151
1201
70
1009
108
759
113
1451
31
171
190
2039
38
5
183
2205
35
176
172
2033
104
805
98
1363
144
1321
37
711
Addiction caused by alcohol UNS
F10.29 [2000501684]
3.5e+00
—
—
1.0e+50
1.0e+50
—
4.0e+00
cases:9.95%
controls:0.32%
—
—
—
—
cases:2.26%
controls:0.00%
cases:2.42%
controls:0.00%
—
—
cases:16.57%
controls:0.34%
22
7
199
2203
—
—
5
0
216
2210
5
0
202
2209
—
30
7
151
2025
Chronic alcohol abuse
P15 [2002000811]
3.6e+00
—
—
—
—
—
3.6e+00
cases:7.69%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
cases:8.29%
controls:0.25%
17
5
204
2205
—
—
—
—
—
15
5
166
2027
Depressive episode, unspecified
F32.9 [45571760]
2.3e+00
—
—
—
—
2.7e+00
2.1e+00
cases:7.69%
controls:0.81%
—
—
—
—
—
—
—
—
cases:3.47%
controls:0.23%
cases:7.73%
controls:0.98%
17
18
204
2192
—
—
—
—
7
5
195
2163
14
20
167
2012
Cathetrisation of vein
TPH04 [2001309597]
1.5e+00
1.9e+00
—
—
—
2.3e+00
1.4e+00
cases:5.88%
controls:1.36%
cases:4.52%
controls:0.68%
—
—
—
—
—
—
cases:4.46%
controls:0.46%
cases:7.73%
controls:2.02%
13
30
208
2180
10
15
211
2195
—
—
—
9
10
193
2158
14
41
167
1991
citalopram; oral, parenteral
N06AB04 [21604712]
1.8e+00
1.3e+00
—
—
2.6e+00
9.8e-01
1.4e+00
cases:14.48%
controls:2.85%
cases:6.79%
controls:1.86%
—
—
—
—
cases:2.90%
controls:0.23%
cases:3.96%
controls:1.52%
cases:11.60%
controls:3.20%
32
63
189
2147
15
41
206
2169
—
—
6
5
201
2204
8
33
194
2135
21
65
160
1967
Moderate depressive episode without somatic syndrome
F32.10 [2000501980]
2.0e+00
2.5e+00
—
—
—
2.4e+00
1.3e+00
cases:3.17%
controls:0.45%
cases:2.71%
controls:0.23%
—
—
—
—
—
—
cases:2.48%
controls:0.23%
cases:2.76%
controls:0.74%
7
10
214
2200
6
5
215
2205
—
—
—
5
5
197
2163
5
15
176
2017
lamotrigine; oral
N03AX09 [21604431]
2.2e+00
—
—
—
—
2.4e+00
2.3e+00
cases:2.71%
controls:0.32%
—
—
—
—
—
—
—
—
cases:2.97%
controls:0.28%
cases:5.52%
controls:0.59%
6
7
215
2203
—
—
—
—
6
6
196
2162
10
12
171
2020
Exposure to unspecified factor
X59 [45756412]
1.6e+00
2.1e+00
—
—
—
1.9e+00
1.2e+00
cases:8.14%
controls:1.76%
cases:4.52%
controls:0.59%
—
—
—
—
—
—
cases:4.46%
controls:0.69%
cases:7.73%
controls:2.36%
18
39
203
2171
10
13
211
2197
—
—
—
9
15
193
2153
14
48
167
1984
mirtazapine; oral
N06AX11 [21604740]
1.6e+00
1.6e+00
1.7e+00
—
1.5e+00
1.9e+00
1.5e+00
cases:18.10%
controls:4.07%
cases:10.41%
controls:2.26%
cases:3.17%
controls:0.59%
—
—
cases:2.90%
controls:0.63%
cases:14.36%
controls:2.40%
cases:22.65%
controls:6.10%
40
90
181
2120
23
50
198
2160
7
13
214
2197
—
6
14
201
2195
29
52
173
2116
41
124
140
1908
Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 [3026910]
9.6e-01
1.2e+00
1.6e+00
1.0e+50
2.3e+00
1.3e+00
9.3e-01
cases:14.03%
controls:5.88%
cases:10.41%
controls:3.44%
cases:3.17%
controls:0.68%
cases:4.07%
controls:0.00%
cases:3.86%
controls:0.41%
cases:10.89%
controls:3.27%
cases:24.31%
controls:11.22%
31
130
190
2080
23
76
198
2134
7
15
214
2195
9
0
212
2210
8
9
199
2200
22
71
180
2097
44
228
137
1804
propranolol; oral, parenteral
C07AA05 [21601670]
1.7e+00
1.9e+00
—
—
—
1.6e+00
1.3e+00
cases:11.76%
controls:2.44%
cases:9.05%
controls:1.49%
—
—
—
—
—
—
cases:5.45%
controls:1.20%
cases:9.94%
controls:2.85%
26
54
195
2156
20
33
201
2177
—
—
—
11
26
191
2142
18
58
163
1974
oxcarbazepine; oral
N03AF02 [21604418]
3.1e+00
—
1.0e+50
—
—
—
3.3e+00
cases:5.88%
controls:0.27%
—
—
cases:2.71%
controls:0.00%
—
—
—
—
—
—
cases:7.18%
controls:0.30%
13
6
208
2204
—
6
0
215
2210
—
—
—
13
6
168
2026
Poisoning by systemic antibiotics
T36 [45756588]
2.9e+00
—
—
—
—
—
3.3e+00
cases:5.43%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
cases:8.29%
controls:0.34%
12
7
209
2203
—
—
—
—
—
15
7
166
2025
General Surgery
2 [38004447]
9.7e-01
1.1e+00
1.6e+00
—
1.8e+00
1.3e+00
9.6e-01
cases:39.37%
controls:19.82%
cases:17.19%
controls:6.29%
cases:3.17%
controls:0.68%
—
—
cases:3.38%
controls:0.59%
cases:17.82%
controls:5.63%
cases:35.91%
controls:17.62%
87
438
134
1772
38
139
183
2071
7
15
214
2195
—
7
13
200
2196
36
122
166
2046
65
358
116
1674
Open wound of scalp
S01.0 [45592468]
3.0e+00
—
—
—
—
—
2.9e+00
cases:9.50%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
cases:7.73%
controls:0.44%
21
12
200
2198
—
—
—
—
—
14
9
167
2023
Intentional self-poisoning by and exposure to other and unspecified chemicals and noxious substances
X69 [45585661]
2.7e+00
—
—
—
—
—
3.2e+00
cases:4.52%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
cases:6.63%
controls:0.30%
10
7
211
2203
—
—
—
—
—
12
6
169
2026
Office Visit
OMOP4822458 [581477]
1.1e+00
1.5e+00
—
—
—
1.7e+00
1.5e+00
cases:15.84%
controls:6.06%
cases:8.60%
controls:2.04%
—
—
—
—
—
—
cases:11.39%
controls:2.26%
cases:24.86%
controls:6.89%
35
134
186
2076
19
45
202
2165
—
—
—
23
49
179
2119
45
140
136
1892
Laboratory Visit
OMOP4822461 [32036]
2.0e-01
3.5e-01
7.4e-01
4.3e+00
1.4e+00
4.0e-01
5.8e-03
cases:18.55%
controls:15.75%
cases:20.81%
controls:15.66%
cases:9.95%
controls:5.02%
cases:14.93%
controls:0.23%
cases:16.91%
controls:4.57%
cases:23.27%
controls:16.84%
cases:33.15%
controls:33.02%
41
348
180
1862
46
346
175
1864
22
111
199
2099
33
5
188
2205
35
101
172
2108
47
365
155
1803
60
671
121
1361
Concussion
S06.0 [45582805]
3.2e+00
—
—
—
—
—
2.3e+00
cases:8.14%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
cases:7.18%
controls:0.79%
18
8
203
2202
—
—
—
—
—
13
16
168
2016
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
4.8e-01
7.2e-01
1.5e+00
—
2.4e+00
7.8e-01
4.4e-01
cases:15.38%
controls:10.14%
cases:15.38%
controls:8.14%
cases:5.88%
controls:1.31%
—
—
cases:11.11%
controls:1.13%
cases:15.35%
controls:7.70%
cases:27.07%
controls:19.24%
34
224
187
1986
34
180
187
2030
13
29
208
2181
—
23
25
184
2184
31
167
171
2001
49
391
132
1641
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
4.5e-01
8.3e-01
1.4e+00
—
2.0e+00
7.4e-01
4.7e-01
cases:16.29%
controls:11.00%
cases:19.00%
controls:9.32%
cases:7.24%
controls:1.81%
—
—
cases:12.56%
controls:1.86%
cases:17.82%
controls:9.36%
cases:32.04%
controls:22.74%
36
243
185
1967
42
206
179
2004
16
40
205
2170
—
26
41
181
2168
36
203
166
1965
58
462
123
1570
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
1.0e+00
1.5e+00
—
—
—
1.2e+00
1.3e+00
cases:10.86%
controls:4.12%
cases:8.60%
controls:2.13%
—
—
—
—
—
—
cases:6.93%
controls:2.21%
cases:19.89%
controls:6.15%
24
91
197
2119
19
47
202
2163
—
—
—
14
48
188
2120
36
125
145
1907
Unspecified fall
W19 [45756257]
2.5e+00
—
—
—
—
—
2.5e+00
cases:5.43%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
cases:8.29%
controls:0.74%
12
10
209
2200
—
—
—
—
—
15
15
166
2017
Supplier / Service Provider
OMOP5117446 [33004]
-7.6e-01
-7.4e-01
-1.0e+50
—
—
2.7e+00
3.1e+00
cases:14.03%
controls:25.88%
cases:3.62%
controls:7.33%
cases:0.00%
controls:0.50%
—
—
—
—
cases:4.46%
controls:0.32%
cases:11.05%
controls:0.54%
31
572
190
1638
8
162
213
2048
0
11
221
2199
—
—
9
7
193
2161
20
11
161
2021
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
4.5e-01
8.2e-01
1.5e+00
—
2.0e+00
7.3e-01
4.6e-01
cases:16.29%
controls:11.09%
cases:19.00%
controls:9.37%
cases:7.24%
controls:1.76%
—
—
cases:12.56%
controls:1.90%
cases:17.82%
controls:9.50%
cases:32.04%
controls:22.88%
36
245
185
1965
42
207
179
2003
16
39
205
2171
—
26
42
181
2167
36
206
166
1962
58
465
123
1567
Emergency Room and Inpatient Visit
ERIP [262]
1.1e+00
2.0e+00
—
1.0e+50
—
1.5e+00
1.3e+00
cases:4.52%
controls:1.58%
cases:5.88%
controls:0.81%
—
—
cases:3.62%
controls:0.00%
—
—
cases:4.95%
controls:1.20%
cases:9.39%
controls:2.85%
10
35
211
2175
13
18
208
2192
—
8
0
213
2210
—
10
26
192
2142
17
58
164
1974
aPTT in Platelet poor plasma by Coagulation assay
14979-9 [3018677]
1.3e+00
2.5e+00
—
—
—
—
2.1e+00
cases:3.62%
controls:1.04%
cases:4.98%
controls:0.41%
—
—
—
—
—
—
—
—
cases:9.94%
controls:1.28%
8
23
213
2187
11
9
210
2201
—
—
—
—
18
26
163
2006
zopiclone; oral
N05CF01 [21604654]
1.7e+00
8.3e-01
—
—
1.8e+00
9.2e-01
1.1e+00
cases:23.08%
controls:5.07%
cases:6.79%
controls:3.08%
—
—
—
—
cases:3.86%
controls:0.63%
cases:7.43%
controls:3.09%
cases:17.13%
controls:6.55%
51
112
170
2098
15
68
206
2142
—
—
8
14
199
2195
15
67
187
2101
31
133
150
1899
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
3.8e-01
7.3e-01
1.1e+00
—
1.9e+00
8.4e-01
2.2e-01
cases:14.48%
controls:10.41%
cases:15.84%
controls:8.33%
cases:6.33%
controls:2.26%
—
—
cases:11.59%
controls:1.86%
cases:19.80%
controls:9.59%
cases:25.97%
controls:22.05%
32
230
189
1980
35
184
186
2026
14
50
207
2160
—
24
41
183
2168
40
208
162
1960
47
448
134
1584
Other and unspecified abdominal pain
R10.4 [45568113]
1.2e+00
1.7e+00
—
—
—
1.3e+00
1.4e+00
cases:10.41%
controls:3.26%
cases:4.98%
controls:0.95%
—
—
—
—
—
—
cases:2.97%
controls:0.83%
cases:13.81%
controls:3.79%
23
72
198
2138
11
21
210
2189
—
—
—
6
18
196
2150
25
77
156
1955
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]
1.4e+00
1.7e+00
—
—
—
1.2e+00
1.3e+00
cases:10.41%
controls:2.85%
cases:5.43%
controls:1.09%
—
—
—
—
—
—
cases:4.95%
controls:1.48%
cases:12.71%
controls:3.94%
23
63
198
2147
12
24
209
2186
—
—
—
10
32
192
2136
23
80
158
1952
oxazepam; oral
N05BA04 [21604569]
1.4e+00
1.6e+00
1.5e+00
—
—
9.9e-01
1.2e+00
cases:11.76%
controls:3.12%
cases:7.24%
controls:1.49%
cases:2.71%
controls:0.59%
—
—
—
—
cases:4.95%
controls:1.89%
cases:11.60%
controls:3.74%
26
69
195
2141
16
33
205
2177
6
13
215
2197
—
—
10
41
192
2127
21
76
160
1956
Epilepsy
G40 [45595935]
—
—
—
—
—
—
4.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:13.81%
controls:0.25%
—
—
—
—
—
—
25
5
156
2027
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
1.3e+00
1.5e+00
—
—
—
1.2e+00
1.3e+00
cases:7.69%
controls:2.26%
cases:4.98%
controls:1.13%
—
—
—
—
—
—
cases:3.47%
controls:1.11%
cases:8.84%
controls:2.61%
17
50
204
2160
11
25
210
2185
—
—
—
7
24
195
2144
16
53
165
1979
pantoprazole; oral, parenteral
A02BC02 [21600097]
9.7e-01
8.5e-01
—
—
1.2e+00
1.2e+00
1.0e+00
cases:20.81%
controls:9.10%
cases:12.67%
controls:5.84%
—
—
—
—
cases:4.35%
controls:1.36%
cases:16.83%
controls:5.63%
cases:30.94%
controls:13.93%
46
201
175
2009
28
129
193
2081
—
—
9
30
198
2179
34
122
168
2046
56
283
125
1749
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
5.6e-01
6.9e-01
1.2e+00
—
1.8e+00
8.9e-01
3.0e-01
cases:14.48%
controls:8.82%
cases:14.48%
controls:7.83%
cases:5.88%
controls:1.90%
—
—
cases:11.11%
controls:1.95%
cases:16.34%
controls:7.43%
cases:22.65%
controls:17.86%
32
195
189
2015
32
173
189
2037
13
42
208
2168
—
23
43
184
2166
33
161
169
2007
41
363
140
1669
clonazepam; oral, parenteral
N03AE01 [21604415]
1.8e+00
2.0e+00
—
—
—
—
1.9e+00
cases:3.17%
controls:0.54%
cases:2.26%
controls:0.32%
—
—
—
—
—
—
—
—
cases:5.52%
controls:0.84%
7
12
214
2198
5
7
216
2203
—
—
—
—
10
17
171
2015
Bacterial infection, unspecified
A49.9 [45590816]
1.7e+00
-1.0e+50
—
—
—
—
2.0e+00
cases:4.07%
controls:0.77%
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
cases:4.42%
controls:0.64%
9
17
212
2193
0
5
221
2205
—
—
—
—
8
13
173
2019
Alcohol-related acute intoxication uncomplicated
F10.00 [2000501668]
3.6e+00
—
—
—
—
—
—
cases:7.69%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
17
5
204
2205
—
—
—
—
—
—
levetiracetam; oral, parenteral
N03AX14 [21604436]
—
—
—
—
1.0e+50
—
3.5e+00
—
—
—
—
—
—
—
—
cases:2.42%
controls:0.00%
—
—
cases:10.50%
controls:0.34%
—
—
—
—
5
0
202
2209
—
19
7
162
2025
Epilepsy, unspecified
G40.9 [45562083]
3.4e+00
—
1.0e+50
1.0e+50
1.0e+50
—
—
cases:9.05%
controls:0.32%
—
—
cases:2.71%
controls:0.00%
cases:2.26%
controls:0.00%
cases:2.42%
controls:0.00%
—
—
—
—
20
7
201
2203
—
6
0
215
2210
5
0
216
2210
5
0
202
2209
—
—
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
2.9e-01
5.4e-01
9.8e-01
—
1.8e+00
6.3e-01
1.2e-01
cases:17.19%
controls:13.39%
cases:19.00%
controls:12.08%
cases:7.69%
controls:3.03%
—
—
cases:14.01%
controls:2.67%
cases:21.29%
controls:12.55%
cases:31.49%
controls:28.99%
38
296
183
1914
42
267
179
1943
17
67
204
2143
—
29
59
178
2150
43
272
159
1896
57
589
124
1443
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
1.5e+00
1.7e+00
—
1.0e+50
—
1.8e+00
1.9e+00
cases:4.98%
controls:1.13%
cases:3.17%
controls:0.59%
—
—
cases:2.26%
controls:0.00%
—
—
cases:2.97%
controls:0.51%
cases:8.84%
controls:1.48%
11
25
210
2185
7
13
214
2197
—
5
0
216
2210
—
6
11
196
2157
16
30
165
2002
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
2.9e-01
5.4e-01
9.8e-01
—
1.7e+00
6.4e-01
1.2e-01
cases:17.19%
controls:13.39%
cases:19.00%
controls:12.04%
cases:7.69%
controls:3.03%
—
—
cases:13.53%
controls:2.67%
cases:21.29%
controls:12.50%
cases:31.49%
controls:28.94%
38
296
183
1914
42
266
179
1944
17
67
204
2143
—
28
59
179
2150
43
271
159
1897
57
588
124
1444
Withdrawal symptoms and delirium caused by alcohol without seizures
F10.40 [2000501688]
—
—
—
—
—
1.0e+50
3.4e+00
—
—
—
—
—
—
—
—
—
—
cases:2.48%
controls:0.00%
cases:6.63%
controls:0.25%
—
—
—
—
—
5
0
197
2168
12
5
169
2027
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
2.9e-01
5.4e-01
9.8e-01
—
1.7e+00
6.3e-01
1.2e-01
cases:17.19%
controls:13.39%
cases:19.00%
controls:12.04%
cases:7.69%
controls:3.03%
—
—
cases:13.53%
controls:2.67%
cases:21.29%
controls:12.55%
cases:31.49%
controls:28.99%
38
296
183
1914
42
266
179
1944
17
67
204
2143
—
28
59
179
2150
43
272
159
1896
57
589
124
1443
MCH [Entitic mass]
28539-5 [3035941]
2.9e-01
5.4e-01
9.8e-01
—
1.7e+00
6.3e-01
1.2e-01
cases:17.19%
controls:13.39%
cases:19.00%
controls:12.04%
cases:7.69%
controls:3.03%
—
—
cases:13.53%
controls:2.67%
cases:21.29%
controls:12.55%
cases:31.49%
controls:28.99%
38
296
183
1914
42
266
179
1944
17
67
204
2143
—
28
59
179
2150
43
272
159
1896
57
589
124
1443
Platelets [#/volume] in Blood
26515-7 [3007461]
3.0e-01
5.4e-01
9.8e-01
—
1.7e+00
6.3e-01
1.3e-01
cases:17.19%
controls:13.35%
cases:19.00%
controls:12.04%
cases:7.69%
controls:3.03%
—
—
cases:13.53%
controls:2.67%
cases:21.29%
controls:12.55%
cases:31.49%
controls:28.84%
38
295
183
1915
42
266
179
1944
17
67
204
2143
—
28
59
179
2150
43
272
159
1896
57
586
124
1446
Leukocytes [#/volume] in Blood
26464-8 [3010813]
2.9e-01
5.3e-01
9.8e-01
—
1.7e+00
6.3e-01
1.2e-01
cases:17.19%
controls:13.44%
cases:19.00%
controls:12.13%
cases:7.69%
controls:3.03%
—
—
cases:13.53%
controls:2.67%
cases:21.29%
controls:12.55%
cases:31.49%
controls:28.94%
38
297
183
1913
42
268
179
1942
17
67
204
2143
—
28
59
179
2150
43
272
159
1896
57
588
124
1444
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
3.0e-01
5.4e-01
9.8e-01
—
1.7e+00
6.3e-01
1.1e-01
cases:17.19%
controls:13.35%
cases:19.00%
controls:12.08%
cases:7.69%
controls:3.03%
—
—
cases:13.53%
controls:2.67%
cases:21.29%
controls:12.59%
cases:31.49%
controls:29.08%
38
295
183
1915
42
267
179
1943
17
67
204
2143
—
28
59
179
2150
43
273
159
1895
57
591
124
1441
Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures
G40.29 [2000502142]
—
—
—
—
—
1.0e+50
3.3e+00
—
—
—
—
—
—
—
—
—
—
cases:2.48%
controls:0.00%
cases:6.08%
controls:0.25%
—
—
—
—
—
5
0
197
2168
11
5
170
2027
Alcohol dependence currently independent
F10.20 [2000501677]
3.2e+00
—
—
—
—
—
—
cases:5.43%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
12
5
209
2205
—
—
—
—
—
—
Epilepsy and comparable convulsive disorders
111 [2001600111]
—
—
—
—
—
—
3.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.73%
controls:0.34%
—
—
—
—
—
—
14
7
167
2025
Hypo-osmolality and hyponatraemia
E87.1 [45542779]
—
1.0e+50
—
—
—
—
3.2e+00
—
—
cases:2.71%
controls:0.00%
—
—
—
—
—
—
—
—
cases:5.52%
controls:0.25%
—
6
0
215
2210
—
—
—
—
10
5
171
2027
Alcohol dependence periodic alcoholism
F10.26 [2000501683]
3.1e+00
—
—
—
—
—
—
cases:5.88%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
—
13
6
208
2204
—
—
—
—
—
—
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
6.9e-01
9.7e-01
—
—
2.1e+00
3.4e-01
6.6e-01
cases:9.50%
controls:5.02%
cases:7.69%
controls:3.08%
—
—
—
—
cases:2.90%
controls:0.36%
cases:3.96%
controls:2.86%
cases:15.47%
controls:8.61%
21
111
200
2099
17
68
204
2142
—
—
6
8
201
2201
8
62
194
2106
28
175
153
1857
Case Management Agency
251B00000X [38004193]
3.0e-01
2.9e-01
4.2e-01
3.0e+00
5.6e-01
2.5e-01
3.9e-01
cases:43.44%
controls:36.15%
cases:36.65%
controls:30.18%
cases:14.93%
controls:10.32%
cases:11.31%
controls:0.63%
cases:15.94%
controls:9.73%
cases:38.61%
controls:32.98%
cases:65.75%
controls:56.40%
96
799
125
1411
81
667
140
1543
33
228
188
1982
25
14
196
2196
33
215
174
1994
78
715
124
1453
119
1146
62
886
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
3.6e-01
6.0e-01
1.0e+00
—
1.8e+00
6.1e-01
3.1e-01
cases:16.74%
controls:12.31%
cases:18.55%
controls:11.13%
cases:7.24%
controls:2.67%
—
—
cases:12.56%
controls:2.31%
cases:18.81%
controls:11.21%
cases:32.04%
controls:25.64%
37
272
184
1938
41
246
180
1964
16
59
205
2151
—
26
51
181
2158
38
243
164
1925
58
521
123
1511
chlordiazepoxide; oral, parenteral
N05BA02 [21604567]
—
—
—
—
—
—
2.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.52%
controls:0.34%
—
—
—
—
—
—
10
7
171
2025
Amylase [Enzymatic activity/volume] in Serum or Plasma
1798-8 [3016771]
1.4e+00
1.4e+00
—
—
—
—
1.4e+00
cases:7.24%
controls:1.95%
cases:4.07%
controls:1.00%
—
—
—
—
—
—
—
—
cases:13.26%
controls:3.64%
16
43
205
2167
9
22
212
2188
—
—
—
—
24
74
157
1958
Phosphatidylethanol [Mass/volume] in Blood
74661-0 [44816559]
—
—
—
—
1.0e+50
—
2.7e+00
—
—
—
—
—
—
—
—
cases:2.42%
controls:0.00%
—
—
cases:4.42%
controls:0.30%
—
—
—
—
5
0
202
2209
—
8
6
173
2026
INR in Blood by Coagulation assay
34714-6 [3032080]
5.8e-01
1.6e+00
1.6e+00
1.0e+50
1.9e+00
9.9e-01
1.1e+00
cases:6.33%
controls:3.67%
cases:8.14%
controls:1.72%
cases:2.26%
controls:0.45%
cases:3.17%
controls:0.00%
cases:2.90%
controls:0.45%
cases:4.46%
controls:1.71%
cases:14.92%
controls:5.56%
14
81
207
2129
18
38
203
2172
5
10
216
2200
7
0
214
2210
6
10
201
2199
9
37
193
2131
27
113
154
1919
Pneumonia, unspecified
J18.9 [45601123]
1.4e+00
—
—
1.0e+50
—
—
1.2e+00
cases:5.88%
controls:1.45%
—
—
—
—
cases:2.26%
controls:0.00%
—
—
—
—
cases:7.73%
controls:2.36%
13
32
208
2178
—
—
5
0
216
2210
—
—
14
48
167
1984
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
5.8e-01
8.9e-01
1.1e+00
—
1.6e+00
9.1e-01
8.4e-01
cases:11.31%
controls:6.65%
cases:10.41%
controls:4.57%
cases:2.71%
controls:0.95%
—
—
cases:3.38%
controls:0.68%
cases:10.40%
controls:4.47%
cases:22.65%
controls:11.22%
25
147
196
2063
23
101
198
2109
6
21
215
2189
—
7
15
200
2194
21
97
181
2071
41
228
140
1804
Haematemesis
K92.0 [45605964]
2.6e+00
—
—
—
—
—
—
cases:3.62%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
—
8
6
213
2204
—
—
—
—
—
—
Clinic/Center
261Q00000X [38004207]
—
—
—
—
—
—
2.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.87%
controls:0.30%
—
—
—
—
—
—
7
6
174
2026
Gas panel - Venous blood
24339-4 [3000991]
1.7e+00
—
—
—
—
2.6e+00
1.1e+00
cases:2.26%
controls:0.41%
—
—
—
—
—
—
—
—
cases:2.97%
controls:0.23%
cases:2.76%
controls:0.94%
5
9
216
2201
—
—
—
—
6
5
196
2163
5
19
176
2013
Hemoglobin [Mass/volume] in Arterial blood
30313-1 [3002173]
—
—
—
—
—
2.6e+00
1.3e+00
—
—
—
—
—
—
—
—
—
—
cases:2.97%
controls:0.23%
cases:3.87%
controls:1.03%
—
—
—
—
—
6
5
196
2163
7
21
174
2011
Fracture of upper end of humerus
S42.2 [45544677]
2.5e+00
—
—
—
—
—
—
cases:2.71%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
6
5
215
2205
—
—
—
—
—
—
Laceration/cut
S18 [2002000983]
9.1e-01
—
—
—
—
1.5e+00
9.7e-01
cases:7.24%
controls:3.03%
—
—
—
—
—
—
—
—
cases:4.46%
controls:1.06%
cases:12.71%
controls:5.22%
16
67
205
2143
—
—
—
—
9
23
193
2145
23
106
158
1926
pH of Arterial blood
2744-1 [3019977]
1.3e+00
—
—
1.0e+50
—
2.4e+00
1.4e+00
cases:2.26%
controls:0.63%
—
—
—
—
cases:2.26%
controls:0.00%
—
—
cases:2.97%
controls:0.28%
cases:4.42%
controls:1.18%
5
14
216
2196
—
—
5
0
216
2210
—
6
6
196
2162
8
24
173
2008
Oxygen [Partial pressure] in Arterial blood
2703-7 [3027801]
1.3e+00
—
—
1.0e+50
—
2.4e+00
1.3e+00
cases:2.26%
controls:0.63%
—
—
—
—
cases:2.26%
controls:0.00%
—
—
cases:2.48%
controls:0.23%
cases:4.42%
controls:1.23%
5
14
216
2196
—
—
5
0
216
2210
—
5
5
197
2163
8
25
173
2007
Base excess in Arterial blood by calculation
1925-7 [3003396]
1.3e+00
—
—
1.0e+50
—
2.4e+00
1.3e+00
cases:2.26%
controls:0.63%
—
—
—
—
cases:2.26%
controls:0.00%
—
—
cases:2.48%
controls:0.23%
cases:4.42%
controls:1.23%
5
14
216
2196
—
—
5
0
216
2210
—
5
5
197
2163
8
25
173
2007
Carbon dioxide [Partial pressure] in Arterial blood
2019-8 [3027946]
1.3e+00
—
—
1.0e+50
—
2.4e+00
1.3e+00
cases:2.26%
controls:0.63%
—
—
—
—
cases:2.26%
controls:0.00%
—
—
cases:2.48%
controls:0.23%
cases:4.42%
controls:1.23%
5
14
216
2196
—
—
5
0
216
2210
—
5
5
197
2163
8
25
173
2007
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
3.1e-01
7.3e-01
1.0e+00
—
1.7e+00
6.2e-01
3.2e-01
cases:11.76%
controls:8.87%
cases:14.93%
controls:7.83%
cases:4.98%
controls:1.86%
—
—
cases:8.21%
controls:1.67%
cases:11.88%
controls:6.73%
cases:20.99%
controls:16.14%
26
196
195
2014
33
173
188
2037
11
41
210
2169
—
17
37
190
2172
24
146
178
2022
38
328
143
1704
Amylase.pancreatic [Enzymatic activity/volume] in Serum or Plasma
1805-1 [3016417]
1.4e+00
2.3e+00
—
—
—
—
—
cases:3.17%
controls:0.81%
cases:4.07%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
7
18
214
2192
9
9
212
2201
—
—
—
—
—
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
R29.8 [45587505]
2.3e+00
—
—
—
—
—
—
cases:2.71%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
—
6
6
215
2204
—
—
—
—
—
—
Fall on and from stairs and steps
W10 [45756250]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.31%
controls:0.34%
—
—
—
—
—
—
6
7
175
2025
Intensive care
WX872 [2001310844]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.31%
controls:0.34%
—
—
—
—
—
—
6
7
175
2025
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
9.7e-01
8.6e-01
—
—
1.8e+00
1.2e+00
1.3e+00
cases:7.69%
controls:3.08%
cases:4.98%
controls:2.17%
—
—
—
—
cases:2.42%
controls:0.41%
cases:4.46%
controls:1.38%
cases:15.47%
controls:4.68%
17
68
204
2142
11
48
210
2162
—
—
5
9
202
2200
9
30
193
2138
28
95
153
1937
Pharmacy visit
OMOP4822462 [581458]
8.7e-01
7.6e-01
5.5e-01
5.9e-01
9.2e-01
7.1e-01
9.9e-01
cases:95.48%
controls:89.86%
cases:85.97%
controls:74.16%
cases:47.96%
controls:34.66%
cases:2.26%
controls:1.27%
cases:55.07%
controls:32.87%
cases:86.63%
controls:76.20%
cases:97.24%
controls:92.86%
211
1986
10
224
190
1639
31
571
106
766
115
1444
5
28
216
2182
114
726
93
1483
175
1652
27
516
176
1887
5
145
Treatment of a patient needing special arrangements
WYA30 [2001310874]
1.3e+00
—
—
—
—
—
2.2e+00
cases:2.26%
controls:0.63%
—
—
—
—
—
—
—
—
—
—
cases:6.08%
controls:0.74%
5
14
216
2196
—
—
—
—
—
11
15
170
2017
Respiratory and circulatory monitoring
WX700 [2001310817]
2.1e+00
1.8e+00
—
—
—
—
1.2e+00
cases:7.69%
controls:1.00%
cases:2.71%
controls:0.45%
—
—
—
—
—
—
—
—
cases:4.97%
controls:1.48%
17
22
204
2188
6
10
215
2200
—
—
—
—
9
30
172
2002
Restricted health certificate
SPAT1283 [2001700384]
—
—
—
—
—
2.1e+00
6.1e-01
—
—
—
—
—
—
—
—
—
—
cases:2.97%
controls:0.37%
cases:3.31%
controls:1.82%
—
—
—
—
—
6
8
196
2160
6
37
175
1995
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
3.2e-01
6.6e-01
7.4e-01
—
1.5e+00
5.8e-01
3.3e-01
cases:15.38%
controls:11.63%
cases:16.74%
controls:9.46%
cases:4.98%
controls:2.44%
—
—
cases:6.28%
controls:1.54%
cases:16.34%
controls:9.82%
cases:30.94%
controls:24.41%
34
257
187
1953
37
209
184
2001
11
54
210
2156
—
13
34
194
2175
33
213
169
1955
56
496
125
1536
Epithelial cells.non-squamous [#/volume] in Urine by Automated count
51485-1 [3030306]
1.3e+00
2.1e+00
—
—
—
1.2e+00
4.3e-01
cases:3.17%
controls:0.90%
cases:4.52%
controls:0.59%
—
—
—
—
—
—
cases:2.48%
controls:0.74%
cases:2.76%
controls:1.82%
7
20
214
2190
10
13
211
2197
—
—
—
5
16
197
2152
5
37
176
1995
Upper gastrointestinal surgery
106 [44777669]
6.8e-01
8.1e-01
—
—
—
1.2e+00
8.6e-01
cases:10.41%
controls:5.57%
cases:5.43%
controls:2.49%
—
—
—
—
—
—
cases:7.92%
controls:2.49%
cases:17.13%
controls:8.02%
23
123
198
2087
12
55
209
2155
—
—
—
16
54
186
2114
31
163
150
1869
Other and unspecified symptoms and signs involving cognitive functions and awareness
R41.8 [45534452]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.52%
controls:0.74%
—
—
—
—
—
—
10
15
171
2017
Valproate [Moles/volume] in Serum or Plasma
14946-8 [3009466]
1.9e+00
2.0e+00
—
—
—
—
2.1e+00
cases:2.26%
controls:0.36%
cases:2.26%
controls:0.32%
—
—
—
—
—
—
—
—
cases:4.42%
controls:0.59%
5
8
216
2202
5
7
216
2203
—
—
—
—
8
12
173
2020
Monitored bed care
WX892 [2001310850]
2.0e+00
—
—
—
—
—
1.7e+00
cases:2.71%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
cases:3.31%
controls:0.64%
6
8
215
2202
—
—
—
—
—
6
13
175
2019
Fracture of rib
S22.3 [45573285]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.97%
controls:0.69%
—
—
—
—
—
—
9
14
172
2018
Epithelial cells.squamous [#/volume] in Urine by Automated count
51486-9 [3029879]
1.3e+00
2.0e+00
—
—
—
1.3e+00
6.7e-01
cases:3.17%
controls:0.90%
cases:4.52%
controls:0.63%
—
—
—
—
—
—
cases:2.48%
controls:0.69%
cases:3.31%
controls:1.72%
7
20
214
2190
10
14
211
2196
—
—
—
5
15
197
2153
6
35
175
1997
ECG with 12 standard connections
XF400 [2001303368]
2.0e+00
2.3e+00
—
—
—
—
1.2e+00
cases:9.05%
controls:1.36%
cases:2.26%
controls:0.23%
—
—
—
—
—
—
—
—
cases:3.31%
controls:0.98%
20
30
201
2180
5
5
216
2205
—
—
—
—
6
20
175
2012
Social worker
Z2446 [2001311559]
2.0e+00
—
—
—
—
—
—
cases:4.07%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
—
—
9
13
212
2197
—
—
—
—
—
—
Fall on same level involving ice and snow
W00 [45756242]
2.0e+00
—
—
—
—
—
1.0e+00
cases:4.07%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
cases:2.76%
controls:0.98%
9
13
212
2197
—
—
—
—
—
5
20
176
2012
sertraline; oral
N06AB06 [21604714]
1.9e+00
—
—
—
—
—
1.1e+00
cases:3.62%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
cases:3.31%
controls:1.13%
8
12
213
2198
—
—
—
—
—
6
23
175
2009
levomepromazine; oral, parenteral
N05AA02 [21604493]
1.2e+00
—
—
—
—
1.6e+00
1.9e+00
cases:3.17%
controls:1.00%
—
—
—
—
—
—
—
—
cases:2.97%
controls:0.60%
cases:4.42%
controls:0.69%
7
22
214
2188
—
—
—
—
6
13
196
2155
8
14
173
2018
Neurosurgery
14 [38004459]
1.9e+00
1.6e+00
—
—
—
1.4e+00
8.6e-01
cases:8.60%
controls:1.40%
cases:2.26%
controls:0.45%
—
—
—
—
—
—
cases:2.97%
controls:0.78%
cases:4.42%
controls:1.92%
19
31
202
2179
5
10
216
2200
—
—
—
6
17
196
2151
8
39
173
1993
Orthopedic Surgery
20 [38004465]
4.7e-01
7.0e-01
—
—
1.6e+00
1.0e+00
8.5e-01
cases:15.84%
controls:10.50%
cases:8.14%
controls:4.21%
—
—
—
—
cases:2.90%
controls:0.59%
cases:10.40%
controls:4.11%
cases:26.52%
controls:13.34%
35
232
186
1978
18
93
203
2117
—
—
6
13
201
2196
21
89
181
2079
48
271
133
1761
Essential (primary) hypertension
I10 [45591453]
3.6e-02
5.2e-01
1.8e+00
1.0e+50
—
5.7e-01
3.1e-01
cases:9.95%
controls:9.64%
cases:8.60%
controls:5.29%
cases:3.62%
controls:0.59%
cases:2.71%
controls:0.00%
—
—
cases:7.92%
controls:4.66%
cases:20.44%
controls:15.90%
22
213
199
1997
19
117
202
2093
8
13
213
2197
6
0
215
2210
—
16
101
186
2067
37
323
144
1709
clindamycin; oral, parenteral
J01FF01 [21602985]
5.1e-01
—
—
—
—
1.8e+00
4.0e-01
cases:5.43%
controls:3.35%
—
—
—
—
—
—
—
—
cases:3.96%
controls:0.65%
cases:4.97%
controls:3.40%
12
74
209
2136
—
—
—
—
8
14
194
2154
9
69
172
1963
Malaise and fatigue
R53 [45553741]
1.8e+00
—
—
—
—
—
1.1e+00
cases:4.98%
controls:0.86%
—
—
—
—
—
—
—
—
—
—
cases:4.97%
controls:1.67%
11
19
210
2191
—
—
—
—
—
9
34
172
1998
hydroxyzine; oral, parenteral
N05BB01 [21604590]
1.3e+00
—
—
—
—
—
1.8e+00
cases:4.07%
controls:1.13%
—
—
—
—
—
—
—
—
—
—
cases:4.97%
controls:0.89%
9
25
212
2185
—
—
—
—
—
9
18
172
2014
macrogol; oral
A06AD15 [21600575]
—
-1.0e+50
—
—
—
—
1.8e+00
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
cases:4.97%
controls:0.89%
—
0
7
221
2203
—
—
—
—
9
18
172
2014
Syncope and collapse
R55 [45568141]
1.7e+00
—
—
—
—
—
1.2e+00
cases:4.98%
controls:0.90%
—
—
—
—
—
—
—
—
—
—
cases:3.31%
controls:0.98%
11
20
210
2190
—
—
—
—
—
6
20
175
2012
CBC panel - Blood by Automated count
58410-2 [40761511]
4.7e-01
4.1e-01
7.6e-01
—
1.7e+00
5.0e-01
1.0e-01
cases:16.74%
controls:11.18%
cases:12.22%
controls:8.46%
cases:3.62%
controls:1.72%
—
—
cases:7.73%
controls:1.49%
cases:12.87%
controls:8.26%
cases:24.86%
controls:22.98%
37
247
184
1963
27
187
194
2023
8
38
213
2172
—
16
33
191
2176
26
179
176
1989
45
467
136
1565
fluoxetine; oral
N06AB03 [21604711]
1.3e+00
1.7e+00
—
—
—
—
—
cases:4.98%
controls:1.45%
cases:3.62%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
11
32
210
2178
8
15
213
2195
—
—
—
—
—
Folate [Moles/volume] in Serum or Plasma
14732-2 [3021960]
1.7e+00
1.9e+00
—
—
—
—
9.8e-01
cases:4.07%
controls:0.77%
cases:2.71%
controls:0.41%
—
—
—
—
—
—
—
—
cases:6.63%
controls:2.61%
9
17
212
2193
6
9
215
2201
—
—
—
—
12
53
169
1979
Cathetrisation of artery
TPH07 [2001309747]
1.7e+00
—
—
—
—
—
1.9e+00
cases:4.52%
controls:0.86%
—
—
—
—
—
—
—
—
—
—
cases:3.31%
controls:0.49%
10
19
211
2191
—
—
—
—
—
6
10
175
2022
Lactate [Moles/volume] in Serum or Plasma
2524-7 [3014111]
—
—
—
1.0e+50
—
—
1.6e+00
—
—
—
—
—
—
cases:2.26%
controls:0.00%
—
—
—
—
cases:4.42%
controls:0.89%
—
—
—
5
0
216
2210
—
—
8
18
173
2014
risperidone; oral, parenteral
N05AX08 [21604559]
1.0e+00
—
—
—
—
—
1.6e+00
cases:2.26%
controls:0.81%
—
—
—
—
—
—
—
—
—
—
cases:4.97%
controls:1.03%
5
18
216
2192
—
—
—
—
—
9
21
172
2011
Thorax X-ray examination outside radiological department
GD1UA [2001303652]
1.4e+00
1.6e+00
—
1.0e+50
—
—
1.6e+00
cases:4.07%
controls:1.09%
cases:2.26%
controls:0.45%
—
—
cases:2.71%
controls:0.00%
—
—
—
—
cases:8.84%
controls:1.92%
9
24
212
2186
5
10
216
2200
—
6
0
215
2210
—
—
16
39
165
1993
cefalexin; oral
J01DB01 [21602870]
7.4e-01
6.4e-01
8.5e-01
—
1.7e+00
8.4e-01
3.9e-01
cases:41.18%
controls:24.98%
cases:13.57%
controls:7.65%
cases:2.71%
controls:1.18%
—
—
cases:3.38%
controls:0.63%
cases:18.32%
controls:8.81%
cases:37.02%
controls:28.54%
91
552
130
1658
30
169
191
2041
6
26
215
2184
—
7
14
200
2195
37
191
165
1977
67
580
114
1452
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
1.0e+00
1.6e+00
—
—
—
9.6e-01
6.0e-01
cases:5.88%
controls:2.22%
cases:5.88%
controls:1.27%
—
—
—
—
—
—
cases:2.97%
controls:1.15%
cases:5.52%
controls:3.10%
13
49
208
2161
13
28
208
2182
—
—
—
6
25
196
2143
10
63
171
1969
Pain localized to upper abdomen
R10.1 [45568111]
1.2e+00
—
—
—
—
—
1.6e+00
cases:2.26%
controls:0.72%
—
—
—
—
—
—
—
—
—
—
cases:4.97%
controls:1.08%
5
16
216
2194
—
—
—
—
—
9
22
172
2010
Bacteria [Presence] in Urine
87829-8 [36304419]
1.0e+00
1.5e+00
—
—
—
1.0e+00
5.3e-01
cases:5.43%
controls:2.04%
cases:4.52%
controls:1.00%
—
—
—
—
—
—
cases:2.97%
controls:1.11%
cases:4.42%
controls:2.66%
12
45
209
2165
10
22
211
2188
—
—
—
6
24
196
2144
8
54
173
1978
Folate [Moles/volume] in Red Blood Cells
14731-4 [3019309]
1.1e+00
—
—
—
—
—
1.5e+00
cases:3.62%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
cases:7.73%
controls:1.77%
8
26
213
2184
—
—
—
—
—
14
36
167
1996
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
1.0e+00
1.5e+00
—
—
—
1.0e+00
4.4e-01
cases:5.43%
controls:1.99%
cases:4.98%
controls:1.18%
—
—
—
—
—
—
cases:2.97%
controls:1.11%
cases:4.42%
controls:2.90%
12
44
209
2166
11
26
210
2184
—
—
—
6
24
196
2144
8
59
173
1973
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
7.6e-01
1.5e+00
—
—
—
7.8e-01
4.8e-01
cases:5.43%
controls:2.62%
cases:5.43%
controls:1.31%
—
—
—
—
—
—
cases:2.97%
controls:1.38%
cases:6.08%
controls:3.84%
12
58
209
2152
12
29
209
2181
—
—
—
6
30
196
2138
11
78
170
1954
Dermatitis, unspecified
L30.9 [45572271]
—
—
—
—
—
—
1.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.52%
controls:1.38%
—
—
—
—
—
—
10
28
171
2004
Intravenous general anesthesia
WX404 [2001310807]
1.4e+00
1.2e+00
—
—
—
—
5.7e-01
cases:4.98%
controls:1.27%
cases:2.26%
controls:0.68%
—
—
—
—
—
—
—
—
cases:2.76%
controls:1.57%
11
28
210
2182
5
15
216
2195
—
—
—
—
5
32
176
2000
Plastic And Reconstructive Surgery
24 [38004467]
3.3e-01
—
—
—
-1.0e+50
-1.0e+50
1.4e+00
cases:2.26%
controls:1.63%
—
—
—
—
—
—
cases:0.00%
controls:0.23%
cases:0.00%
controls:0.74%
cases:6.08%
controls:1.57%
5
36
216
2174
—
—
—
0
5
207
2204
0
16
202
2152
11
32
170
2000
Leukocytes [#/volume] in Urine
30405-5 [3018095]
9.7e-01
1.4e+00
—
—
—
8.9e-01
4.8e-01
cases:5.88%
controls:2.31%
cases:5.88%
controls:1.54%
—
—
—
—
—
—
cases:2.97%
controls:1.25%
cases:6.08%
controls:3.84%
13
51
208
2159
13
34
208
2176
—
—
—
6
27
196
2141
11
78
170
1954
Phosphate [Moles/volume] in Serum or Plasma
14879-1 [3003458]
1.2e+00
1.6e+00
—
—
—
—
1.4e+00
cases:3.62%
controls:1.13%
cases:3.17%
controls:0.63%
—
—
—
—
—
—
—
—
cases:6.08%
controls:1.62%
8
25
213
2185
7
14
214
2196
—
—
—
—
11
33
170
1999
Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma
48065-7 [3051714]
7.4e-01
—
—
—
—
—
1.3e+00
cases:2.71%
controls:1.31%
—
—
—
—
—
—
—
—
—
—
cases:7.18%
controls:1.97%
6
29
215
2181
—
—
—
—
—
13
40
168
1992
Gastroenterology
10 [38004455]
1.3e+00
—
—
—
—
7.1e-01
7.6e-01
cases:9.50%
controls:2.67%
—
—
—
—
—
—
—
—
cases:2.97%
controls:1.48%
cases:7.73%
controls:3.79%
21
59
200
2151
—
—
—
—
6
32
196
2136
14
77
167
1955
Other specified chronic obstructive pulmonary disease
J44.8 [45586673]
—
—
-1.0e+50
—
—
—
1.3e+00
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
cases:6.63%
controls:1.87%
—
—
0
5
221
2205
—
—
—
12
38
169
1994
Bacteria identified in Blood by Culture
600-7 [3023368]
1.2e+00
1.4e+00
—
1.0e+50
—
—
1.3e+00
cases:5.43%
controls:1.76%
cases:3.17%
controls:0.77%
—
—
cases:2.26%
controls:0.00%
—
—
—
—
cases:8.84%
controls:2.56%
12
39
209
2171
7
17
214
2193
—
5
0
216
2210
—
—
16
52
165
1980
Troponin I.cardiac [Mass/volume] in Serum or Plasma
10839-9 [3021337]
1.2e+00
1.3e+00
—
—
—
1.1e+00
1.3e+00
cases:4.98%
controls:1.63%
cases:2.71%
controls:0.72%
—
—
—
—
—
—
cases:2.48%
controls:0.88%
cases:8.29%
controls:2.46%
11
36
210
2174
6
16
215
2194
—
—
—
5
19
197
2149
15
50
166
1982
venlafaxine; oral
N06AX16 [21604745]
1.3e+00
5.9e-01
—
—
—
1.0e+00
1.1e+00
cases:5.43%
controls:1.58%
cases:2.26%
controls:1.27%
—
—
—
—
—
—
cases:3.47%
controls:1.25%
cases:6.08%
controls:2.02%
12
35
209
2175
5
28
216
2182
—
—
—
7
27
195
2141
11
41
170
1991
furosemide; oral, parenteral
C03CA01 [21601518]
4.1e-01
3.5e-02
—
—
-1.0e+50
1.3e-01
1.2e+00
cases:4.98%
controls:3.35%
cases:2.71%
controls:2.62%
—
—
—
—
cases:0.00%
controls:0.63%
cases:2.97%
controls:2.63%
cases:12.15%
controls:3.84%
11
74
210
2136
6
58
215
2152
—
—
0
14
207
2195
6
57
196
2111
22
78
159
1954
omeprazole; oral, parenteral
A02BC01 [21600096]
7.2e-01
4.9e-01
—
—
—
5.9e-01
1.2e+00
cases:7.24%
controls:3.67%
cases:2.71%
controls:1.67%
—
—
—
—
—
—
cases:2.97%
controls:1.66%
cases:7.73%
controls:2.36%
16
81
205
2129
6
37
215
2173
—
—
—
6
36
196
2132
14
48
167
1984
Urgent procedure
ZXD05 [2001311386]
1.2e+00
—
—
—
—
1.7e+00
7.6e-01
cases:9.50%
controls:2.94%
—
—
—
—
—
—
—
—
cases:2.48%
controls:0.46%
cases:7.18%
controls:3.49%
21
65
200
2145
—
—
—
—
5
10
197
2158
13
71
168
1961
Home Visit
OMOP4822459 [581476]
1.1e+00
—
-1.0e+50
—
—
1.5e+00
1.2e+00
cases:4.07%
controls:1.36%
—
—
cases:0.00%
controls:0.41%
—
—
—
—
cases:3.47%
controls:0.83%
cases:10.50%
controls:3.49%
9
30
212
2180
—
0
9
221
2201
—
—
7
18
195
2150
19
71
162
1961
Chest pain, unspecified
R07.4 [45558450]
1.2e+00
1.2e+00
—
—
—
—
6.5e-01
cases:7.24%
controls:2.40%
cases:2.26%
controls:0.72%
—
—
—
—
—
—
—
—
cases:5.52%
controls:2.95%
16
53
205
2157
5
16
216
2194
—
—
—
—
10
60
171
1972
General anesthesia, balanced
WX408 [2001310808]
8.8e-01
1.2e+00
—
—
—
—
1.1e+00
cases:5.88%
controls:2.53%
cases:2.26%
controls:0.72%
—
—
—
—
—
—
—
—
cases:7.18%
controls:2.46%
13
56
208
2154
5
16
216
2194
—
—
—
—
13
50
168
1982
Transferrin receptor.soluble [Mass/volume] in Serum or Plasma
30248-9 [3015399]
1.1e+00
—
—
—
—
—
1.1e+00
cases:4.07%
controls:1.45%
—
—
—
—
—
—
—
—
—
—
cases:7.18%
controls:2.46%
9
32
212
2178
—
—
—
—
—
13
50
168
1982
Pain in limb
M79.6 [45587063]
1.1e+00
—
—
—
—
9.1e-01
3.5e-01
cases:6.79%
controls:2.40%
—
—
—
—
—
—
—
—
cases:2.48%
controls:1.01%
cases:6.08%
controls:4.38%
15
53
206
2157
—
—
—
—
5
22
197
2146
11
89
170
1943
Esophagoscopy, gastroscopy and duodenoscopy
UJD10 [2001304788]
9.9e-01
9.7e-01
—
—
—
—
1.1e+00
cases:6.33%
controls:2.44%
cases:3.17%
controls:1.22%
—
—
—
—
—
—
—
—
cases:9.94%
controls:3.64%
14
54
207
2156
7
27
214
2183
—
—
—
—
18
74
163
1958
betamethasone
A07EA04 [21600656]
1.0e+00
6.3e-01
—
—
-1.0e+50
4.2e-01
3.9e-01
cases:12.22%
controls:4.75%
cases:4.07%
controls:2.22%
—
—
—
—
cases:0.00%
controls:0.23%
cases:3.47%
controls:2.31%
cases:9.39%
controls:6.55%
27
105
194
2105
9
49
212
2161
—
—
0
5
207
2204
7
50
195
2118
17
133
164
1899
betamethasone
S02BA07 [21605169]
1.0e+00
6.3e-01
—
—
-1.0e+50
4.2e-01
3.9e-01
cases:12.22%
controls:4.75%
cases:4.07%
controls:2.22%
—
—
—
—
cases:0.00%
controls:0.23%
cases:3.47%
controls:2.31%
cases:9.39%
controls:6.55%
27
105
194
2105
9
49
212
2161
—
—
0
5
207
2204
7
50
195
2118
17
133
164
1899
betamethasone
D07AC01 [21602120]
1.0e+00
6.3e-01
—
—
-1.0e+50
4.2e-01
3.9e-01
cases:12.22%
controls:4.75%
cases:4.07%
controls:2.22%
—
—
—
—
cases:0.00%
controls:0.23%
cases:3.47%
controls:2.31%
cases:9.39%
controls:6.55%
27
105
194
2105
9
49
212
2161
—
—
0
5
207
2204
7
50
195
2118
17
133
164
1899
betamethasone
C05AA05 [21601610]
1.0e+00
6.3e-01
—
—
-1.0e+50
4.2e-01
3.9e-01
cases:12.22%
controls:4.75%
cases:4.07%
controls:2.22%
—
—
—
—
cases:0.00%
controls:0.23%
cases:3.47%
controls:2.31%
cases:9.39%
controls:6.55%
27
105
194
2105
9
49
212
2161
—
—
0
5
207
2204
7
50
195
2118
17
133
164
1899
Troponin T.cardiac [Mass/volume] in Serum or Plasma
6598-7 [3019800]
8.9e-02
1.1e+00
—
1.0e+50
—
—
1.0e+00
cases:2.71%
controls:2.49%
cases:3.17%
controls:1.09%
—
—
cases:2.26%
controls:0.00%
—
—
—
—
cases:9.94%
controls:3.89%
6
55
215
2155
7
24
214
2186
—
5
0
216
2210
—
—
18
79
163
1953
One hour or less
ZXE00 [2001311394]
9.8e-01
1.1e+00
—
—
—
—
3.9e-01
cases:9.50%
controls:3.80%
cases:4.07%
controls:1.45%
—
—
—
—
—
—
—
—
cases:7.18%
controls:4.97%
21
84
200
2126
9
32
212
2178
—
—
—
—
13
101
168
1931
Medical doctor
Z2221 [2001311556]
9.4e-01
4.5e-01
—
—
—
9.7e-01
7.5e-01
cases:8.14%
controls:3.35%
cases:2.26%
controls:1.45%
—
—
—
—
—
—
cases:3.47%
controls:1.34%
cases:6.63%
controls:3.25%
18
74
203
2136
5
32
216
2178
—
—
—
7
29
195
2139
12
66
169
1966
calcium (different salts in combination); oral
A12AA20 [21600872]
3.3e-01
—
-1.0e+50
—
—
—
9.1e-01
cases:4.52%
controls:3.30%
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
cases:10.50%
controls:4.53%
10
73
211
2137
—
0
16
221
2194
—
—
—
19
92
162
1940
hydrocortisone
S02BA01 [21605166]
8.8e-01
5.2e-01
—
—
—
—
7.3e-01
cases:12.22%
controls:5.48%
cases:3.17%
controls:1.90%
—
—
—
—
—
—
—
—
cases:9.94%
controls:5.07%
27
121
194
2089
7
42
214
2168
—
—
—
—
18
103
163
1929
hydrocortisone aceponate
D07AC16 [21602135]
8.2e-01
4.1e-01
—
—
—
4.7e-01
7.3e-01
cases:13.12%
controls:6.24%
cases:3.17%
controls:2.13%
—
—
—
—
—
—
cases:2.48%
controls:1.57%
cases:11.05%
controls:5.66%
29
138
192
2072
7
47
214
2163
—
—
—
5
34
197
2134
20
115
161
1917
hydrocortisone buteprate
D07AB11 [21602115]
8.2e-01
4.1e-01
—
—
—
4.7e-01
7.3e-01
cases:13.12%
controls:6.24%
cases:3.17%
controls:2.13%
—
—
—
—
—
—
cases:2.48%
controls:1.57%
cases:11.05%
controls:5.66%
29
138
192
2072
7
47
214
2163
—
—
—
5
34
197
2134
20
115
161
1917
hydrocortisone
D07AA02 [21602102]
8.2e-01
4.1e-01
—
—
—
4.7e-01
7.3e-01
cases:13.12%
controls:6.24%
cases:3.17%
controls:2.13%
—
—
—
—
—
—
cases:2.48%
controls:1.57%
cases:11.05%
controls:5.66%
29
138
192
2072
7
47
214
2163
—
—
—
5
34
197
2134
20
115
161
1917
hydrocortisone butyrate
D07AB02 [21602106]
8.2e-01
4.1e-01
—
—
—
4.7e-01
7.3e-01
cases:13.12%
controls:6.24%
cases:3.17%
controls:2.13%
—
—
—
—
—
—
cases:2.48%
controls:1.57%
cases:11.05%
controls:5.66%
29
138
192
2072
7
47
214
2163
—
—
—
5
34
197
2134
20
115
161
1917
hydrocortisone
A07EA02 [21600654]
8.0e-01
4.1e-01
—
—
—
4.7e-01
7.7e-01
cases:13.12%
controls:6.38%
cases:3.17%
controls:2.13%
—
—
—
—
—
—
cases:2.48%
controls:1.57%
cases:11.60%
controls:5.71%
29
141
192
2069
7
47
214
2163
—
—
—
5
34
197
2134
21
116
160
1916
hydrocortisone
C05AA01 [21601608]
8.0e-01
4.1e-01
—
—
—
4.7e-01
7.7e-01
cases:13.12%
controls:6.38%
cases:3.17%
controls:2.13%
—
—
—
—
—
—
cases:2.48%
controls:1.57%
cases:11.60%
controls:5.71%
29
141
192
2069
7
47
214
2163
—
—
—
5
34
197
2134
21
116
160
1916
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
4.8e-01
5.9e-01
4.2e-01
—
7.7e-01
2.7e-01
7.3e-01
cases:26.24%
controls:18.01%
cases:14.93%
controls:8.87%
cases:2.26%
controls:1.49%
—
—
cases:2.42%
controls:1.13%
cases:12.87%
controls:10.10%
cases:44.20%
controls:27.66%
58
398
163
1812
33
196
188
2014
5
33
216
2177
—
5
25
202
2184
26
219
176
1949
80
562
101
1470
ibuprofen
R02AX02 [1588667]
4.7e-01
6.5e-01
2.7e-01
—
4.9e-01
1.5e-01
3.9e-01
cases:40.27%
controls:29.68%
cases:21.72%
controls:12.67%
cases:2.71%
controls:2.08%
—
—
cases:2.42%
controls:1.49%
cases:16.34%
controls:14.44%
cases:44.20%
controls:34.99%
89
656
132
1554
48
280
173
1930
6
46
215
2164
—
5
33
202
2176
33
313
169
1855
80
711
101
1321
ibuprofen; oral, parenteral, rectal
M01AE01 [21603967]
4.7e-01
6.5e-01
2.7e-01
—
4.9e-01
1.5e-01
3.9e-01
cases:40.27%
controls:29.68%
cases:21.72%
controls:12.67%
cases:2.71%
controls:2.08%
—
—
cases:2.42%
controls:1.49%
cases:16.34%
controls:14.44%
cases:44.20%
controls:34.99%
89
656
132
1554
48
280
173
1930
6
46
215
2164
—
5
33
202
2176
33
313
169
1855
80
711
101
1321
Health check-up performed based on health survey in students of universities, universities of applied sciences etc.
SPAT1366 [2001700467]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
221
2204
—
—
—
—
—
—
Benign neoplasm: Ascending colon
D12.2 [45600580]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.25%
—
—
—
—
—
—
0
5
181
2027
beclometasone; nasal
R01AD01 [21605043]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.67%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.28%
cases:0.00%
controls:1.13%
0
37
221
2173
—
—
—
—
0
6
202
2162
0
23
181
2009
Hepatitis A virus IgM Ab [Presence] in Serum
22314-9 [3013327]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.25%
—
—
—
—
—
—
0
5
181
2027
Other or unspecified generalized epileptic syndromes with atonic, clonic, myoclonic or tonic-clonic seizures
G40.39 [2000502150]
—
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:2.48%
controls:0.00%
—
—
—
—
—
—
—
5
0
197
2168
—
flucloxacillin; oral, parenteral
J01CF05 [21602857]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
0
7
181
2025
Laparoscopic cholecystectomy
JKA21 [2001305294]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
221
2203
—
—
—
—
—
—
Reticulocytes/Erythrocytes in Blood
4679-7 [3027945]
—
-1.0e+50
—
—
—
—
1.4e+00
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
cases:4.42%
controls:1.13%
—
0
9
221
2201
—
—
—
—
8
23
173
2009
Zoster without complication
B02.9 [45581143]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
0
7
181
2025
Issue of medical certificate
Z02.7 [45537613]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
221
2205
—
—
—
—
—
—
Abdominal pain localized other
D06 [2002000305]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
221
2204
—
—
—
—
—
—
Fear of hypertension
K25 [2002000553]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
221
2205
—
—
—
—
—
—
Demanding periodontal treatment
SDA04 [2001310329]
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
cases:0.00%
controls:1.01%
—
—
—
—
—
—
0
5
207
2204
0
22
202
2146
—
Hemolysis interference index of Serum or Plasma
46424-8 [3052851]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
221
2199
—
—
—
—
—
—
encephalitis, tick borne, inactivated, whole virus
J07BA01 [21601331]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.28%
—
0
8
221
2202
—
—
—
—
0
26
181
2006
Melanocytic naevi
D22 [45595739]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
0
10
181
2022
Cutaneous abscess, furuncle and carbuncle
L02 [45538561]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.25%
—
—
—
—
—
—
0
5
181
2027
Cholesterol in LDL [Moles/volume] in Serum or Plasma
22748-8 [3001308]
-1.7e-01
-3.3e-01
—
—
—
-3.6e-01
-8.3e-02
cases:9.50%
controls:11.04%
cases:5.88%
controls:7.96%
—
—
—
—
—
—
cases:5.94%
controls:8.30%
cases:21.55%
controls:22.98%
21
244
200
1966
13
176
208
2034
—
—
—
12
180
190
1988
39
467
142
1565
enoxaparin; parenteral
B01AB05 [21600976]
—
—
—
—
—
—
1.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.73%
controls:3.00%
—
—
—
—
—
—
14
61
167
1971
semaglutide; oral, parenteral
A10BJ06 [1501778]
-1.0e+50
-1.0e+50
-1.0e+50
—
—
-1.0e+50
—
cases:0.00%
controls:0.27%
cases:0.00%
controls:0.36%
cases:0.00%
controls:0.23%
—
—
—
—
cases:0.00%
controls:0.60%
—
—
0
6
221
2204
0
8
221
2202
0
5
221
2205
—
—
0
13
202
2155
—
Combined first trimester screening
MA3AE [2001306839]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
0
5
202
2163
—
Metamyelocytes/Leukocytes in Blood
28541-1 [3002179]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
221
2202
—
—
—
—
—
—
Blepharochalasis
H02.3 [45586340]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
221
2204
—
—
—
—
—
—
Asthma
J45 [45596282]
8.8e-01
-1.0e+50
—
—
—
—
4.0e-01
cases:2.26%
controls:0.95%
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
cases:2.76%
controls:1.87%
5
21
216
2189
0
8
221
2202
—
—
—
—
5
38
176
1994
candesartan and diuretics
C09DA06 [21601838]
-1.0e+50
-1.0e+50
-1.0e+50
—
-1.0e+50
-1.0e+50
—
cases:0.00%
controls:0.95%
cases:0.00%
controls:1.09%
cases:0.00%
controls:0.23%
—
—
cases:0.00%
controls:0.41%
cases:0.00%
controls:1.15%
—
—
0
21
221
2189
0
24
221
2186
0
5
221
2205
—
0
9
207
2200
0
25
202
2143
—
flumetasone and antiinfectives
S02CA02 [21605174]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
0
11
181
2021
Diabetic background retinopathy
H36.00 [2000502320]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
0
8
181
2024
Melanocytic naevi of upper limb, including shoulder
D22.6 [45590987]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.25%
—
—
—
—
—
—
0
5
181
2027
Ear pain/earache
H01 [2002000475]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
0
6
202
2162
—
budesonide; inhalant
R03BA02 [21603285]
-7.5e-02
4.8e-01
—
—
—
4.4e-01
5.2e-01
cases:3.62%
controls:3.89%
cases:3.17%
controls:1.99%
—
—
—
—
—
—
cases:3.47%
controls:2.26%
cases:6.63%
controls:4.04%
8
86
213
2124
7
44
214
2166
—
—
—
7
49
195
2119
12
82
169
1950
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
6.1e-01
7.7e-01
-1.0e+50
—
—
2.7e-01
5.9e-01
cases:6.79%
controls:3.80%
cases:5.43%
controls:2.58%
cases:0.00%
controls:0.54%
—
—
—
—
cases:3.47%
controls:2.68%
cases:10.50%
controls:6.10%
15
84
206
2126
12
57
209
2153
0
12
221
2198
—
—
7
58
195
2110
19
124
162
1908
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Blood
47598-8 [3048816]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
0
7
202
2161
—
Acute suppurative otitis media
H66.0 [45572040]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
0
6
181
2026
Acute apical periodontitis of pulpal origin
K04.4 [45567286]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.63%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
0
14
221
2196
—
—
—
—
0
6
202
2162
—
Sprain and strain of other and unspecified parts of knee
S83.6 [45579536]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
221
2203
—
—
—
—
—
—
SMOKING - SMOKE2: no - SMOKE3: Unspecified - SMOKE5: Unspecified
SMOKING-2-0-0 [2002330112]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
221
2199
—
—
—
—
—
—
Preventive oral health care, extensive
SCA03 [2001310304]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.25%
—
—
—
—
—
—
0
5
181
2027
Ultrasound examination of mammary glands
HA1AE [2001303886]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
221
2203
—
—
—
—
—
—
Infiltration anesthesia
WX110 [2001310767]
1.1e-01
1.8e-01
—
—
—
9.4e-02
3.8e-01
cases:10.41%
controls:9.46%
cases:4.98%
controls:4.21%
—
—
—
—
—
—
cases:5.45%
controls:4.98%
cases:19.89%
controls:14.52%
23
209
198
2001
11
93
210
2117
—
—
—
11
108
191
2060
36
295
145
1737
salbutamol; inhalant
R03AC02 [21603256]
2.6e-01
4.4e-01
—
—
—
6.6e-01
3.8e-01
cases:9.50%
controls:7.51%
cases:6.33%
controls:4.16%
—
—
—
—
—
—
cases:8.42%
controls:4.52%
cases:15.47%
controls:11.12%
21
166
200
2044
14
92
207
2118
—
—
—
17
98
185
2070
28
226
153
1806
prednisolone
A07EA01 [21600653]
5.2e-01
-5.0e-02
—
—
—
7.3e-02
2.8e-01
cases:8.60%
controls:5.29%
cases:2.71%
controls:2.85%
—
—
—
—
—
—
cases:2.97%
controls:2.77%
cases:10.50%
controls:8.12%
19
117
202
2093
6
63
215
2147
—
—
—
6
60
196
2108
19
165
162
1867
Gout
M10 [45533711]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
0
13
181
2019
Cutaneous abscess, furuncle and carbuncle of limb
L02.4 [45552967]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
0
7
181
2025
Abdominal CT examination
JN3AD [2001305554]
—
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.31%
controls:0.54%
—
—
—
—
—
—
6
11
175
2021
chloramphenicol
S02AA01 [21605147]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
221
2199
—
—
—
—
—
—
Migraine, unspecified
G43.9 [45595943]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
0
7
181
2025
ranitidine bismuth citrate; oral
A02BA07 [21600088]
7.6e-01
—
—
—
—
—
8.6e-01
cases:4.52%
controls:2.17%
—
—
—
—
—
—
—
—
—
—
cases:3.31%
controls:1.43%
10
48
211
2162
—
—
—
—
—
6
29
175
2003
Diverticular disease of large intestine without perforation or abscess
K57.3 [45567316]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
0
8
202
2160
—
Comprehensive monitoring of chronic illness
SPAT1250 [2001700351]
-1.9e-01
-1.0e+50
—
—
—
—
-2.9e-01
cases:2.26%
controls:2.71%
cases:0.00%
controls:1.76%
—
—
—
—
—
—
—
—
cases:3.31%
controls:4.38%
5
60
216
2150
0
39
221
2171
—
—
—
—
6
89
175
1943
Cells panel - Urine sediment
58434-2 [40761535]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
221
2199
—
—
—
—
—
—
Vitreous haemorrhage
H43.1 [45543053]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
0
7
221
2203
—
—
—
—
—
0
8
181
2024
fusidic acid
D09AA02 [21602265]
1.0e+00
—
—
—
—
-1.0e+50
4.3e-01
cases:4.52%
controls:1.72%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
cases:2.76%
controls:1.82%
10
38
211
2172
—
—
—
—
0
13
202
2155
5
37
176
1995
pseudoephedrine, combinations; oral
R01BA52 [21603213]
-4.8e-01
—
-1.0e+50
—
-1.0e+50
—
-7.4e-01
cases:4.98%
controls:7.78%
—
—
cases:0.00%
controls:0.23%
—
—
cases:0.00%
controls:0.27%
—
—
cases:3.31%
controls:6.69%
11
172
210
2038
—
0
5
221
2205
—
0
6
207
2203
—
6
136
175
1896
Cystitis
N30 [45563012]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
0
10
181
2022
Periodontal treatment by dental hygienist
SDE02 [2001310350]
—
-1.0e+50
—
—
—
—
-3.4e-02
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
cases:2.76%
controls:2.85%
—
0
15
221
2195
—
—
—
—
5
58
176
1974
Sampling
SPAT1263 [2001700364]
-5.7e-02
2.3e-01
—
—
—
6.7e-01
4.3e-01
cases:3.17%
controls:3.35%
cases:2.26%
controls:1.81%
—
—
—
—
—
—
cases:3.47%
controls:1.80%
cases:7.18%
controls:4.77%
7
74
214
2136
5
40
216
2170
—
—
—
7
39
195
2129
13
97
168
1935
nedocromil; inhalant
R03BC03 [21603299]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
221
2203
—
—
—
—
—
—
Carcinoembryonic Ag [Mass/volume] in Serum or Plasma
2039-6 [3003785]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
0
7
221
2203
—
—
—
—
—
perindopril; oral
C09AA04 [21601788]
-1.0e+50
-1.0e+50
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.72%
cases:0.00%
controls:0.59%
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
0
16
221
2194
0
13
221
2197
—
—
0
6
207
2203
—
—
Transpostion, tenodesis, shortening or lengthening of tendon of shoulder or upper arm
NBL68 [2001307348]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.25%
—
—
—
—
—
—
0
5
181
2027
lidocaine; ointment
D04AB01 [21602020]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
0
7
181
2025
Plastic repair of ligament of knee not using prosthetic material, anterior cruciate, arthroscopic
NGE35 [2001308121]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
221
2205
—
—
—
—
—
—
Contact with other and unspecified machinery
W31 [45756284]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.25%
—
—
—
—
—
—
0
5
181
2027
Preventive oral health care, short
SCA01 [2001310302]
—
-1.0e+50
—
—
—
—
8.6e-02
—
—
cases:0.00%
controls:0.63%
—
—
—
—
—
—
—
—
cases:3.31%
controls:3.05%
—
0
14
221
2196
—
—
—
—
6
62
175
1970
Exploration of knee joint, arthroscopic
NGA30 [2001308091]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.77%
—
—
—
—
—
—
—
—
—
—
—
—
0
17
221
2193
—
—
—
—
—
—
metronidazole; vaginal
G01AF01 [21602392]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
0
5
221
2205
—
—
—
—
—
Normoblasts [#/volume] in Blood
715-3 [3021589]
6.7e-01
7.4e-01
—
—
—
—
2.0e-01
cases:6.33%
controls:3.35%
cases:5.43%
controls:2.67%
—
—
—
—
—
—
—
—
cases:6.63%
controls:5.51%
14
74
207
2136
12
59
209
2151
—
—
—
—
12
112
169
1920
Short blood count panel - Blood
55429-5 [40758558]
9.5e-01
—
-1.0e+50
—
—
—
6.9e-01
cases:5.43%
controls:2.17%
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
cases:4.97%
controls:2.56%
12
48
209
2162
—
0
8
221
2202
—
—
—
9
52
172
1980
Atopic dermatitis
L20 [45557698]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
0
6
181
2026
cough suppressants and mucolytics
R05FB01 [21603441]
5.0e-01
—
—
—
—
—
—
cases:3.62%
controls:2.22%
—
—
—
—
—
—
—
—
—
—
—
—
8
49
213
2161
—
—
—
—
—
—
mometasone, combinations
R01AD59 [947911]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
0
7
181
2025
Internal derangement of knee, unspecified
M23.9 [45567507]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
0
7
221
2203
—
—
—
—
—
Sedation and analgesia
WX002 [2001310758]
1.1e+00
—
—
—
—
—
—
cases:2.71%
controls:0.90%
—
—
—
—
—
—
—
—
—
—
—
—
6
20
215
2190
—
—
—
—
—
—
Neuralgia and neuritis, unspecified
M79.2 [45548502]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
0
6
181
2026
Other healthcare associate professional
Z3229 [2001311561]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
0
7
202
2161
—
Single live birth
Z37.0 [45571346]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
0
11
181
2021
moxonidine; oral
C02AC05 [21600401]
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
0
7
221
2203
0
5
221
2205
—
—
—
—
Stress incontinence
N39.3 [45539046]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
221
2205
—
—
—
—
—
—
Haemorrhoids, unspecified
K64.9 [45581909]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
221
2205
—
—
—
—
—
—
Neutrophil cytoplasmic Ab [Units/volume] in Serum
5128-4 [3001334]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
0
7
181
2025
False labour before 37 completed weeks of gestation
O47.0 [45582556]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
221
2203
—
—
—
—
—
—
No disease
A97 [2002000230]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
0
5
221
2205
—
—
—
—
—
ofloxacin
S01AE01 [43534856]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.25%
0
7
221
2203
—
—
—
—
—
0
5
181
2027
Spondylosis, unspecified
M47.9 [45557887]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.32%
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.25%
0
7
221
2203
0
5
221
2205
—
—
—
—
0
5
181
2027
Periodic check-up in occupational healthcare
SPAT1368 [2001700469]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.25%
—
—
—
—
—
—
0
5
181
2027
Overall medication plan or its review
SPAT1252 [2001700353]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
0
10
181
2022
Colonoscopy Study observation
28023-0 [3022145]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.94%
—
0
8
221
2202
—
—
—
—
0
19
181
2013
Transferrin [Mass/volume] in Serum or Plasma
3034-6 [3004789]
1.2e+00
—
—
—
—
—
9.7e-01
cases:2.71%
controls:0.86%
—
—
—
—
—
—
—
—
—
—
cases:4.42%
controls:1.72%
6
19
215
2191
—
—
—
—
—
8
35
173
1997
acrivastine; oral
R06AX18 [21603518]
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
cases:0.00%
controls:1.80%
—
—
—
—
—
—
0
6
207
2203
0
39
202
2129
—
Lipemic interference index of Serum or Plasma
46425-5 [3051611]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
221
2205
—
—
—
—
—
—
Cystitis, unspecified
N30.9 [45606488]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
221
2205
—
—
—
—
—
—
losartan and diuretics
C09DA01 [21601834]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
0
12
207
2197
—
—
Triglyceride [Moles/volume] in Serum or Plasma --fasting
47210-0 [3048773]
-3.0e-01
-2.2e-01
-1.0e+50
—
—
-9.5e-01
-1.0e-01
cases:7.69%
controls:10.14%
cases:4.98%
controls:6.15%
cases:0.00%
controls:1.22%
—
—
—
—
cases:2.48%
controls:6.13%
cases:17.68%
controls:19.19%
17
224
204
1986
11
136
210
2074
0
27
221
2183
—
—
5
133
197
2035
32
390
149
1642
Atrial fibrillation/flutter
K78 [2002000605]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
0
6
202
2162
—
Other post-traumatic gonarthrosis
M17.3 [45567470]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.25%
—
—
—
—
—
—
0
5
181
2027
intermediate-acting sulfonamides - combinations
J01EC20 [21602948]
5.0e-01
—
—
—
—
—
—
cases:3.62%
controls:2.22%
—
—
—
—
—
—
—
—
—
—
—
—
8
49
213
2161
—
—
—
—
—
—
Periodontal treatment, brief
SDA02 [2001310327]
-1.0e+50
—
—
—
—
—
-2.0e-01
cases:0.00%
controls:2.04%
—
—
—
—
—
—
—
—
—
—
cases:3.31%
controls:4.04%
0
45
221
2165
—
—
—
—
—
6
82
175
1950
Balloon angioplasty and metallic stent
AN3 [2000200165]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.32%
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
0
7
221
2203
0
5
221
2205
—
—
—
—
—
Primary total prosthetic replacement of hip joint not using cement
NFB30 [2001307921]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.54%
0
8
221
2202
—
—
—
—
—
0
11
181
2021
hydroxocobalamin; parenteral
B03BA03 [21601123]
—
—
-1.0e+50
—
—
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
cases:0.00%
controls:0.78%
—
—
—
—
0
5
221
2205
—
—
0
17
202
2151
—
Bacteria identified in Isolate by Culture
43409-2 [3042936]
1.5e+00
—
—
—
—
—
7.1e-01
cases:3.62%
controls:0.81%
—
—
—
—
—
—
—
—
—
—
cases:2.76%
controls:1.38%
8
18
213
2192
—
—
—
—
—
5
28
176
2004
ramipril; oral
C09AA05 [21601789]
1.1e-01
-7.5e-02
—
—
—
-1.5e-01
-7.8e-03
cases:5.43%
controls:4.89%
cases:3.62%
controls:3.89%
—
—
—
—
—
—
cases:3.47%
controls:4.01%
cases:7.18%
controls:7.23%
12
108
209
2102
8
86
213
2124
—
—
—
7
87
195
2081
13
147
168
1885
Thorax CT examination
GD1AD [2001303618]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
221
2205
—
—
—
—
—
—
Ambulatory ECG
XF404 [2001303370]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
0
12
181
2020
Very demanding periodontal treatment
SDA05 [2001310330]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
0
10
221
2200
—
—
—
—
—
0
8
181
2024
Sarcoidosis of lung
D86.0 [45576422]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
cases:0.00%
controls:0.30%
—
—
—
—
—
0
5
202
2163
0
6
181
2026
Parkinson disease
G20 [45538098]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
cases:0.00%
controls:0.34%
—
—
—
—
—
0
5
202
2163
0
7
181
2025
Iron [Moles/volume] in Serum or Plasma
14798-3 [3022948]
1.3e+00
—
—
—
—
—
1.0e+00
cases:2.71%
controls:0.77%
—
—
—
—
—
—
—
—
—
—
cases:4.42%
controls:1.62%
6
17
215
2193
—
—
—
—
—
8
33
173
1999
Nonorganic sleep disorders
F51 [45552491]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
0
6
181
2026
dextromethorphan, combinations; oral
N07XX59 [43534835]
5.0e-01
—
—
—
—
—
—
cases:3.62%
controls:2.22%
—
—
—
—
—
—
—
—
—
—
—
—
8
49
213
2161
—
—
—
—
—
—
Emergency care or similar visit
WYA10 [2001310872]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
0
13
181
2019
Prostate specific Ag [Mass/volume] in Serum or Plasma
2857-1 [3013603]
-6.2e-01
-4.2e-01
—
—
—
—
-3.5e-01
cases:2.71%
controls:4.93%
cases:2.26%
controls:3.39%
—
—
—
—
—
—
—
—
cases:6.63%
controls:9.15%
6
109
215
2101
5
75
216
2135
—
—
—
—
12
186
169
1846
Dorsalgia
M54 [45553203]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
0
6
221
2204
—
—
—
—
—
Hand/finger symptom/complaint
L12 [2002000636]
1.2e+00
—
—
—
—
—
—
cases:2.26%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
—
—
5
15
216
2195
—
—
—
—
—
—
orphenadrine (citrate); oral, parenteral
M03BC01 [21604112]
2.6e-01
4.9e-01
—
—
—
—
-3.8e-02
cases:5.88%
controls:4.62%
cases:2.71%
controls:1.67%
—
—
—
—
—
—
—
—
cases:6.08%
controls:6.30%
13
102
208
2108
6
37
215
2173
—
—
—
—
11
128
170
1904
Removal of sutures from oral mucosa
SXB00 [2001310580]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
9
181
2023
felodipine; oral
C08CA02 [21601748]
8.5e-02
2.8e-01
—
—
—
3.3e-01
—
cases:2.26%
controls:2.08%
cases:2.26%
controls:1.72%
—
—
—
—
—
—
cases:2.48%
controls:1.80%
—
—
5
46
216
2164
5
38
216
2172
—
—
—
5
39
197
2129
—

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
144
1941
0.26
19.03
5.0
5.3
1.40
1.36
mmol/l
0.44
135
1821
50
127
4.80
18.93
3.5
1.5
0.51
0.35
mg/l
0.98
39
62
134
1878
0.27
18.82
4.6
4.5
1.42
1.34
mmol/l
0.43
125
1755
147
1941
0.28
17.01
5.3
5.4
4.49
4.54
mmol/l
0.21
139
1832
151
1961
0.27
16.58
6.0
6.0
2.47
2.69
mmol/l
2.08
144
1848
67
262
3.23
13.35
8.5
9.4
0.87
0.87
mmol/l
0.00
55
219
68
270
3.19
13.19
8.9
9.2
7.42
7.42
ph
0.08
43
150
117
650
2.70
11.91
5.3
2.9
60.62
64.22
u/l
0.18
112
611
149
1877
0.37
10.29
5.5
5.1
6.14
6.05
mmol/l
0.31
139
1749
64
284
2.76
9.86
1.7
1.6
1061.49
1231.71
nmol/l
0.86
55
222
69
342
2.48
8.34
2.1
2.1
29.43
29.50
s
0.04
64
335
96
554
2.30
8.19
5.0
4.6
7.40
7.40
ph
0.16
77
392
11
7
16.44
7.30
3.4
2.6
47.18
61.14
umol/l
—
11
7
135
940
2.12
6.76
12.7
8.5
1.18
1.20
mmol/l
3.40
123
826
69
371
2.25
6.75
3.4
2.9
496.21
574.77
mosm/kgh2o
2.07
62
322
95
581
2.11
6.71
5.7
4.8
—
—
—
0
0
46
855
0.42
6.64
4.7
3.2
—
—
—
0
0
24
78
3.33
6.26
4.0
1.5
—
—
—
0
0
156
1859
0.45
6.24
6.6
6.5
39.05
39.70
mmol/mol
0.29
145
1776
24
79
3.29
6.13
4.0
1.5
—
—
—
0
0
24
79
3.29
6.13
3.9
1.5
—
—
—
0
0
23
74
3.35
6.09
4.1
1.6
—
—
—
0
0
174
1985
0.42
5.96
31.2
14.5
—
—
—
0
0
38
732
0.42
5.75
2.6
3.1
0.59
0.73
ug/l
1.14
28
453
16
33
5.14
5.55
2.6
1.4
—
—
—
0
0
23
79
3.13
5.49
4.0
1.5
—
—
—
0
0
66
375
2.08
5.48
7.3
3.9
431.44
337.21
ng/l
0.09
56
297
8
7
11.79
4.82
5.4
1.1
—
—
—
0
0
31
136
2.49
4.71
9.3
4.8
—
—
—
0
0
47
248
2.14
4.67
3.4
3.5
11.95
9.59
umol/l
0.30
40
224
39
192
2.25
4.59
9.2
10.1
—
—
—
0
0
72
447
1.91
4.55
3.7
2.8
—
—
—
0
0
126
939
1.80
4.34
12.7
12.7
1.13
1.23
inr
2.60
116
785
35
170
2.26
4.25
6.5
3.0
4.54
4.65
kpa
0.13
35
165
40
206
2.15
4.21
7.4
3.9
7.38
7.39
ph
1.42
23
118
26
115
2.43
3.89
5.1
3.2
23.52
24.24
mmol/l
0.48
26
115
116
864
1.72
3.84
7.4
5.9
33.26
35.74
g/l
3.80
111
822
43
709
0.51
3.83
1.9
2.1
—
—
—
0
0
84
584
1.71
3.50
4.0
6.9
—
—
—
0
0
67
439
1.76
3.43
4.6
3.5
1.02
1.02
kg/l
1.34
51
297
69
456
1.75
3.43
2.9
2.1
2.31
2.92
mg/l
2.04
60
409
25
116
2.30
3.37
4.4
2.5
2.20
1.23
%
1.58
25
116
144
1162
1.69
3.34
5.7
3.9
7856.40
43.68
e6/l
—
5
22
24
113
2.26
3.14
4.8
2.5
0.69
0.62
%
0.51
24
113
66
443
1.70
3.07
3.6
2.5
5.79
3.66
e6/l
0.91
61
400
14
52
2.81
2.95
1.5
1.6
138.67
288.62
ug/g
—
6
33
56
364
1.72
2.91
2.1
1.8
117647457.51
50160189.66
pmol/l
0.23
51
313
149
1709
0.61
2.90
4.7
4.5
2.01
2.00
mu/l
0.02
139
1577
11
34
3.35
2.77
7.0
3.7
1.55
2.23
mmol/l
—
6
22
11
34
3.35
2.77
7.0
3.7
8.88
8.48
kpa
0.56
11
34
11
34
3.35
2.77
7.0
3.7
4.93
4.99
kpa
0.09
11
34
173
1899
0.59
2.51
32.8
16.4
29.34
24.96
mg/l
0.94
157
1568
13
52
2.59
2.40
7.5
3.4
7.38
7.41
ph
2.02
13
52
11
41
2.77
2.24
7.1
3.1
—
—
—
0
0
81
637
1.43
1.73
4.7
3.2
39.04
156.86
e6/l
0.61
65
498
37
248
1.59
1.69
1.9
1.6
—
—
—
0
0
119
1370
0.72
1.67
3.8
3.6
14.16
14.74
pmol/l
1.93
113
1257
80
637
1.40
1.57
2.8
2.5
—
—
—
0
0
69
863
0.71
1.57
2.0
2.0
1.36
1.43
mmol/l
0.31
59
735
5
15
3.38
1.53
2.2
1.4
—
—
—
0
0
87
708
1.38
1.49
5.6
3.7
33.66
162.03
e6/l
1.29
66
516
108
912
1.36
1.46
3.2
2.9
—
—
estimate
—
0
0
5
16
3.17
1.44
1.2
1.5
—
—
—
0
0
97
807
1.36
1.44
4.6
3.3
6.34
6.14
ph
1.16
60
481
43
576
0.69
1.41
1.4
1.4
—
—
—
0
0
6
24
2.54
1.31
3.5
2.1
14.12
11.48
%
—
6
24
118
1023
1.33
1.29
4.7
3.5
0.17
0.00
estimate
0.48
23
208
8
36
2.27
1.25
1.1
1.4
—
—
—
0
0
6
25
2.44
1.25
5.3
3.8
101.00
104.60
mmol/l
—
6
25
6
25
2.44
1.25
5.3
3.8
4.12
4.13
mmol/l
—
6
25
6
25
2.44
1.25
5.3
3.8
1.17
1.19
mmol/l
—
6
25
68
546
1.35
1.24
4.9
3.1
0.35
0.47
e6/l
0.33
55
407
10
186
0.52
1.24
1.3
1.5
—
—
—
0
0
5
19
2.67
1.22
1.2
1.5
—
—
—
0
0
6
129
0.45
1.20
1.2
1.2
83.50
343.38
u/ml
—
6
115
35
252
1.46
1.18
1.4
1.3
—
—
—
0
0
55
434
1.36
1.11
1.8
1.8
1.11
1.49
mg/l
0.53
43
345
11
59
1.91
1.09
3.1
3.1
63.77
62.12
%
0.08
11
59
13
74
1.80
1.09
2.5
2.0
23.98
24.71
mmol/l
0.25
13
74
7
32
2.23
1.09
5.7
2.1
13.29
10.53
mmol/l
—
7
32
57
695
0.76
1.01
3.5
3.4
89.07
66.83
mg/l
0.16
33
476
5
23
2.20
0.98
1.0
1.6
—
—
—
0
0
0
31
0.00
0.97
0.0
1.2
—
—
—
0
0
6
29
2.10
0.90
1.7
3.0
34.00
33.31
pg
—
6
29
8
42
1.94
0.89
1.1
1.1
—
—
—
0
0
17
247
0.66
0.85
1.5
1.4
—
—
—
0
0
54
443
1.29
0.84
4.4
3.4
—
0.40
—
0
5
42
333
1.32
0.83
2.7
2.1
—
—
—
0
0
13
81
1.64
0.83
3.4
3.4
23.75
25.04
mmol/l
0.77
13
76
115
1032
1.24
0.83
4.8
3.5
0.00
0.00
estimate
-0.00
22
183
66
557
1.26
0.82
5.2
3.5
0.00
0.03
estimate
0.78
22
192
113
1014
1.23
0.81
4.8
3.4
0.00
0.00
estimate
-0.00
23
208
11
174
0.61
0.80
1.1
2.1
0.00
0.00
estimate
—
5
35
16
232
0.67
0.80
1.3
1.6
—
—
—
0
0
0
25
0.00
0.79
0.0
1.2
—
—
—
0
0
0
25
0.00
0.79
0.0
1.0
—
3.17
—
0
12
0
26
0.00
0.79
0.0
1.1
—
—
—
0
0
0
27
0.00
0.78
0.0
1.3
—
161.16
—
0
27
14
91
1.57
0.77
1.6
1.2
—
—
—
0
0
6
34
1.79
0.77
7.2
3.3
15.12
11.80
pmol/l
—
6
34
0
28
0.00
0.76
0.0
1.2
—
—
—
0
0
61
713
0.80
0.75
4.2
4.1
20.24
10.33
mg/mmol
0.34
37
484
24
317
0.73
0.73
1.3
1.3
22.33
38.97
iu/ml
—
9
99
154
1437
1.24
0.72
9.0
3.6
140.18
57.36
u/l
3.87
149
1372
78
883
0.82
0.70
19.2
12.5
0.00
0.00
e9/l
0.53
62
726
5
27
1.87
0.69
4.2
4.8
2.08
4.00
nmol/l
—
5
27
89
793
1.20
0.65
6.7
3.8
32.84
35.86
ng/l
0.09
67
584
32
396
0.78
0.63
1.3
1.4
3.99
2.74
g/l
2.28
23
256
87
777
1.20
0.62
5.2
3.4
0.00
0.02
estimate
0.68
19
176
5
30
1.68
0.62
1.2
1.6
—
—
—
0
0
5
30
1.68
0.62
3.6
3.3
4.52
4.35
e9/l
—
5
30
5
30
1.68
0.62
1.2
1.6
—
—
—
0
0
5
30
1.68
0.62
1.2
1.6
—
—
—
0
0
5
30
1.68
0.62
1.2
1.6
—
—
—
0
0
0
20
0.00
0.60
0.0
2.0
—
34.63
—
0
20
0
20
0.00
0.60
0.0
1.3
—
—
—
0
0
0
20
0.00
0.60
0.0
1.2
—
—
—
0
0
34
275
1.28
0.60
1.8
1.7
—
—
—
0
0
0
22
0.00
0.59
0.0
1.3
—
—
—
0
0
0
22
0.00
0.59
0.0
1.5
—
0.18
—
0
15
15
106
1.45
0.59
3.1
3.1
—
—
—
0
0
0
23
0.00
0.58
0.0
1.0
—
6.08
—
0
11
0
23
0.00
0.58
0.0
1.3
—
—
—
0
0
69
607
1.20
0.57
2.9
4.2
2.32
2.35
mmol/l
0.92
59
552
23
177
1.33
0.57
3.3
4.9
0.00
0.16
%
—
6
49
31
252
1.27
0.53
1.9
1.8
—
—
—
0
0
18
135
1.36
0.53
1.9
1.9
—
—
—
0
0
24
191
1.29
0.49
3.2
4.8
1.29
0.92
%
—
7
64
10
68
1.49
0.48
12.1
10.9
—
—
—
0
0
7
48
1.47
0.47
1.3
1.2
—
—
—
0
0
7
50
1.41
0.45
1.1
1.2
—
—
—
0
0
7
104
0.66
0.40
1.1
1.2
—
—
—
0
0
0
18
0.00
0.40
0.0
2.0
—
—
—
0
0
0
18
0.00
0.40
0.0
1.1
—
—
—
0
0
89
821
1.14
0.40
4.2
2.8
213.97
167.97
ug/l
0.97
83
777
20
246
0.79
0.39
1.2
1.3
—
—
—
0
0
5
36
1.40
0.38
1.4
2.4
—
—
—
0
0
38
330
1.18
0.37
4.2
2.9
1.72
1.04
e6/l
0.50
19
176
90
839
1.12
0.33
2.7
2.0
87.18
95.80
pmol/l
1.02
60
460
18
146
1.25
0.33
6.8
3.4
—
—
—
0
0
74
682
1.13
0.33
4.7
6.9
—
—
—
0
0
18
147
1.24
0.32
2.4
1.8
6.54
6.01
ph
1.00
13
99
7
52
1.36
0.31
4.1
5.2
—
—
—
0
0
31
269
1.18
0.31
1.7
1.4
—
—
—
0
0
14
174
0.79
0.31
1.6
1.4
—
—
—
0
0
38
338
1.15
0.29
2.2
3.3
2.44
2.44
mmol/l
0.04
33
298
5
73
0.68
0.26
1.2
1.2
—
—
—
0
0
69
735
0.91
0.23
4.0
3.3
7.88
8.84
mmol/l
0.62
58
636
5
40
1.26
0.22
3.6
3.0
62.20
56.39
%
—
5
40
38
345
1.12
0.22
2.1
1.9
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
0.47
—
0
5
0
10
0.00
0.21
0.0
1.3
—
211.97
—
0
10
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.6
—
154.38
—
0
13
0
14
0.00
0.20
0.0
2.4
—
5.39
—
0
14
61
572
1.09
0.20
4.8
2.9
0.00
0.01
estimate
0.50
17
164
98
938
1.08
0.20
5.3
7.1
0.63
0.68
%
0.47
92
880
21
184
1.16
0.20
3.1
4.7
1.50
0.39
%
—
6
60
43
465
0.91
0.19
4.6
5.4
—
—
—
0
0
98
940
1.08
0.18
5.2
7.1
3.15
2.92
%
0.35
93
889
98
942
1.07
0.17
5.4
7.1
9.43
9.16
%
0.41
93
891
137
1405
0.93
0.16
4.6
4.1
—
0.20
—
0
5
11
129
0.84
0.15
1.1
1.2
—
—
—
0
0
9
82
1.10
0.15
3.1
2.6
—
—
—
0
0
38
405
0.93
0.13
1.3
1.3
0.74
0.97
u/ml
0.77
12
122
10
87
1.16
0.09
1.5
1.7
—
—
—
0
0
5
48
1.04
0.09
1.2
1.4
—
—
—
0
0
115
1129
1.04
0.07
8.7
11.9
4.23
4.14
e9/l
0.18
101
985
27
255
1.07
0.07
2.7
2.9
4.12
7.30
e9/l
0.79
27
220
11
121
0.90
0.06
1.0
1.3
—
55.02
—
0
12
57
555
1.04
0.05
2.4
2.9
354.00
362.39
umol/l
0.21
50
492
16
169
0.94
0.03
1.4
1.7
—
—
—
0
0
105
1040
1.02
0.02
5.1
7.0
1.81
1.87
e9/l
0.30
93
912
13
137
0.95
0.01
1.3
2.6
—
—
—
0
0
103
1024
1.01
0.00
5.0
7.0
0.67
0.61
e9/l
1.46
88
873
13
133
0.98
0.00
1.9
2.5
—
16.56
—
0
13
103
1028
1.00
0.00
5.0
7.0
0.05
0.04
e9/l
0.36
88
879
105
1053
0.99
0.00
5.8
7.2
0.22
0.20
e9/l
0.37
93
920
14
135
1.04
0.00
4.3
3.3
—
—
—
0
0
27
272
0.99
0.00
1.4
1.4
613.33
424.85
titre
—
6
66
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
2.5
—
23.78
—
0
6
0
6
0.00
0.00
0.0
1.8
—
62.67
—
0
6
0
6
0.00
0.00
0.0
1.7
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
28.50
—
0
8
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.8
—
7.00
—
0
5
6
68
0.88
-0.00
1.7
1.3
—
5.28
—
0
5
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.8
—
194.28
—
0
5
0
5
0.00
-0.00
0.0
1.8
—
27.00
—
0
5
0
7
0.00
-0.00
0.0
1.3
—
10.94
—
0
7
0
9
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
6
61
0.98
-0.00
1.3
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0

Mortality – FinRegistry

↥

Association

Association between endpoint EPISEIZALCO and mortality.

Females

Parameter HR [95% CI] p-value
EPISEIZALCO 9.296 [7.52, 11.49] < 0.001
Birth year 0.996 [0.99, 1.0] 0.38

During the follow-up period (1.1.1998 — 31.12.2019), 231 out of 611 females with EPISEIZALCO died.

Males

Parameter HR [95% CI] p-value
EPISEIZALCO 6.956 [6.12, 7.91] < 0.001
Birth year 0.985 [0.98, 0.99] 0.002

During the follow-up period (1.1.1998 — 31.12.2019), 1235 out of 2499 males with EPISEIZALCO died.

Mortality risk

Mortality risk for people of age

years, who have EPISEIZALCO.

N-year risk Females Males
1 1.35% 1.289%
5 5.042% 6.949%
10 12.988% 16.759%
15 22.412% 29.851%
20 38.968% 47.135%

Relationships between endpoints

↥

Index endpoint: EPISEIZALCO – Epileptic seizures related to alcohol

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data